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A B S T R A C T
Background
People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as
well as acute exacerbations with associated morbidity and healthcare costs.
Objectives
To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.
Search methods
We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified
terms. Searches are current to November 2016.
Selection criteria
We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal
conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.
Data collection and analysis
We used standard Cochrane methodological procedures. For meta-analyses, we subgrouped studies by vaccine type.
Main results
For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171
participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory
volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and
reporting bias as low, and risks of performance and detection bias as moderate.
Compared with control, the vaccine group had a lower likelihood of developing community-acquired pneumonia (CAP) (odds ratio
(OR) 0.62, 95% confidence interval (CI) 0.43 to 0.89; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically
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for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed
to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 21 (95% CI 15 to 74). Mortality from
cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888;
GRADE: moderate), nor did all-cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate).
The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups.
Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446;
GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one
study (n = 181) compared the efficacy of different vaccine types - 23-valent PPV versus 7-valent PCV - and reported no differences for
CAP, all-cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of
some mild adverse effects of vaccination with PPV-23.
Authors’ conclusions
Injectable polyvalent pneumococcal vaccination provides significant protection against community-acquired pneumonia, although
no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event.
Vaccination reduced the likelihood of a COPD exacerbation, and moderate-quality evidence suggests the benefits of pneumococcal
vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.
P L A I N L A N G U A G E S U M M A R Y
Do injectable pneumococcal vaccines prevent pneumonia in people with COPD?
We wanted to find out if pneumococcal vaccination for people with chronic obstructive pulmonary disease (COPD) reduces the risk
of pneumonia and associated mortality. We found a total of 12 studies including 2171 participants. Evidence gathered in this review
is current to December 2015.
Background
People with COPD are at increased risk of respiratory illness such as pneumonia due to a bacterium called Streptococcus pneumoniae,
other community-acquired pneumonias and acute COPD exacerbations. These illnesses increase mortality and are associated with
increased healthcare costs.
Study characteristics
For this updated review, we identified five new studies (606 participants), bringing the total number of studies to 12, involving 2171
participants with COPD. The average age of participants was 66 years, 67% were male and participants had received a diagnosis of
moderate to severe COPD. Eleven studies compared an injectable vaccine versus a control, and one study compared two different types
of injectable vaccine.
Key results
People who were vaccinated were less likely to experience an episode of community-acquired pneumonia; 21 people with COPD (95%
confidence interval (CI) 15 to 74) would have to be vaccinated to prevent one episode of pneumonia. Vaccination made no difference
in the risk of pneumococcal pneumonia due to S pneumoniae or in the chance of dying or of being admitted to hospital. People who
were vaccinated were less likely to experience a COPD exacerbation; eight people with COPD (95% CI 5 to 58) would have to be
vaccinated to prevent one person from having an acute exacerbation. We found no difference in effectiveness between the two types of
injectable vaccine.
Quality of the evidence
Evidence in this review is generally independent and reliable, and we are moderately certain about the results.
Conclusions
In line with current guidance, this review suggests that all people with COPD should be given pneumococcal vaccination to provide
some protection against community-acquired pneumonia, and to reduce the chance of an acute exacerbation.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Is pneumococcal vaccinat ion ef fect ive in prevent ing pneumonia in chronic obstruct ive pulmonary disease?
Patient or population: pat ients with COPD
Setting: community
Intervention: pneumococcal vaccine
Comparison: control
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with control Risk with pneumococ-
cal vaccine
Pneumonia, community
acquired, at least 1
episode
Follow-up: range 6 to 36
months
143 per 1000 94 per 1000
(67 to 129)
OR 0.62
(0.43 to 0.89)
1372
(6 RCTs)
⊕⊕⊕©
Moderatea
Study lim itat ions with
lack of part icipant
blinding and no use
of placebo in 3 stud-
ies. NNTB to prevent 1
episode of CAP = 21
(95% CI 15 to 74)
Pneumococcal pneu-
monia, at least 1
episode
Follow-up: range 6 to 36
months
11 per 1000 3 per 1000
(1 to 14)
OR 0.26
(0.05 to 1.31)
1158
(3 RCTs)
⊕⊕©©
Lowb,c
Very few conf irmed
episodes of pneu-
mococcal pneumonia.
Rate of pneumococcal
CAP to total CAP f rom
2008 to 2013 varied
f rom 17.1% to 37.3% of
cases (Rodrigo 2015).
Death f rom cardiorespi-
ratory causes
Follow-up: range 24 to
48 months
98 per 1000 104 per 1000
(70 to 153)
OR 1.07
(0.69 to 1.66)
888
(3 RCTs)
⊕⊕⊕©
Moderated
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Death f rom all causes
Follow-up: range 12 to
48 months
165 per 1000 165 per 1000
(125 to 217)
OR 1.00
(0.72 to 1.40)
1053
(5 RCTs)
⊕⊕⊕©
Moderated
Hospital ad-
mission: any cause, at
least 1 episode
Follow-up: range 6 to 12
months
86 per 1000 65 per 1000
(29 to 140)
OR 0.74
(0.32 to 1.74)
391
(3 RCTs)
⊕⊕⊕©
Moderated
COPD exacerbat ion: at
least 1 episode
Follow-up: range 6 to 24
months
608 per 1000 482 per 1000
(377 to591)
OR 0.60 (0.39 to 0.93) 446
(4 RCTs)
⊕⊕⊕©
Moderatea
Study lim itat ions with
lack of or unclear par-
t icipant blinding in 3
studies. NNTB = 8 (95%
CI 5 to 58); see Figure 1
Lung funct ion: FEV1 (L)
Follow-up: 12 months
Mean lung funct ion:
FEV1 (L) was 1.43 L
Mean lung funct ion:
FEV1 (L) in the interven-
t ion group was 0.12 L
lower (7.17 lower to 6.
93 greater)
- 142
(1 RCT)
⊕⊕©©
Lowd,e
No dif ference in lung
funct ion seen at 3 or 24
months in 1 study
* The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NNTB: number needed to treat for an addit ional benef icial outcome; OR: odds rat io
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aStudy lim itat ions increase risk of performance and detect ion bias.
bsubstant ial heterogeneity present.
cWide conf idence interval; f ew events in 2 studies, no events in 1 study.
dWide conf idence interval; ef fect size includes the null.
eSingle study.4
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Figure 1. In the control group, 608 out of 1000 people had one or more exacerbations over 6 to 24 months,
compared with 482 (95% CI 377 to 591) out of 1000 for the active treatment group.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is characterised
by airflow obstruction that is not fully reversible. Data from 12
countries in the Burden of Lung Disease (BOLD) initiative show
that more than 10% of adults have COPD at Stage II or higher,
as defined by GOLD 2016. Prevalence and staging vary across
countries between men and women (Buist 2007) and increase
with age. Worldwide, COPD was the fifth- leading cause of death
in 2011, and it was the seventh-leading cause of lost disability-
adjusted life years (DALYs) (WHO 2013).
Exacerbations and comorbidities contribute to the variable natural
history of COPD in individual patients (GOLD 2016). Exacerba-
tions contribute to long-termdecline in lung function (Donaldson
2002) and reduced physical activity (Donaldson 2005).They have
a profound and long-lasting effect on quality of life (Groenewegen
2001; Seemungal 1998) and contribute to increased risk of death
(Soler-Cataluna 2005). Exacerbations are a major contributor
to healthcare costs, especially for hospital admission (Wedzicha
2003).
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The clinical onset of an acute exacerbation is defined according
to symptoms, although definitions vary (Rodriguez-Roisin 2000).
Anthonisen defined type 1 exacerbations on the basis of three
major symptoms: increased dyspnoea, sputum volume and spu-
tum purulence. Type 2 exacerbations required two major symp-
toms, and type 3 exacerbations required one major symptom plus
cough, wheeze or symptoms of an upper respiratory tract infection
(Anthonisen 1987). A later definition required an increase in two
’major symptoms’ of dyspnoea - sputum volume and sputum pu-
rulence - or an increase in one major symptom and in one ’minor
symptom’ for two days (wheeze, sore throat, cough or common
cold symptoms) (Seemungal 2000). Researchers recently devel-
oped a standardised measure for assessing the frequency, severity
and duration of exacerbations of COPD using patient-reported
outcomes as described in clinical studies (Leidy 2010).
Patients with COPDwith persistent lower airway bacterial coloni-
sation when stable are at increased risk of exacerbations (Bogaert
2004; Patel 2002). Infection is frequently detected during exac-
erbations; one study found that 48.4% of participants had viral
causes and 54.7% had bacterial causes of infection (Papi 2006).
Infection-associated exacerbations required longer hospitalisation
and resulted in greater impairment of lung function than exacer-
bations in which no infection was present (Papi 2006). Investiga-
tors in one study (Patel 2002) recovered Streptococcus pneumoniae
(S pneumoniae) from the sputum of 33% of participants. Risk of
exacerbations of COPD is increased among patients with pneu-
mococcal colonisation (Bogaert 2004). Researchers have discov-
ered an association between detection of S pneumoniae as a new
organism in the sputum of patients with COPD and significantly
increased risk of an exacerbation (Sethi 2002).
Pneumonia is usually a serious illness, and diagnosis is based on
the presence of radiological infiltrates, symptoms (cough, expec-
toration, fever, dyspnoea, pleuritic pain, altered mental status),
signs of pulmonary consolidation on auscultation and leukocytosis
(Ochoa-Gondar 2008). Community-acquired pneumonia (CAP)
is amajor health problem among adults over 65 years of age (Welte
2009), and prevalence of 14 cases per 1000 person-years (95%
confidence interval (CI) 12.7 to 15.3) has been reported. Hospi-
talisation rate is high (75%), and in-patient stays are often lengthy
(mean 10.4 days) (Ochoa-Gondar 2008). Overall mortality es-
timates are high: 6% in Canada, 20% in the USA and Spain,
13% in the UK and 8% in Sweden (File 2003; Mandell 2007).
Patients with COPD who develop CAP have more severe pneu-
monia, are admitted to the intensive care unit more frequently
and have significantly higher 30- and 90-day mortality than non-
COPD patients (Molinos 2009; Restrepo 2006). S pneumoniae is
the predominant pathogen among all patients with CAP (Mandell
2007) and among patients with COPD and CAP, for whom a
43% pneumococcal aetiology has been found (Lieberman 2002;
Torres 1996). Progression fromCOPD to CAP has been shown to
be strongly associated with the presence of S pneumoniae (57.3%),
and other pathogens were predominant among exacerbations that
did not progress to CAP (61.7%) (File 2009).
Description of the intervention
On the basis of differences in polysaccharide capsules, investiga-
tors have identified 91 different serotypes of S pneumoniae. Cap-
sule polysaccharides have antiphagocytic activity, which affects the
pathogenesis of invasive pneumococcal disease (IPD), including
CAP (Postma 2012), and the incidence of IPD differs between
serotypes. In the late 1970s, a 14-valent pneumococcal polysac-
charide vaccine (PPV-14) was registered in the United States; this
was replaced in the 1980s by a 23-valent pneumococcal polysac-
charide vaccine (PPV-23) (Pneumovax/Pneumo 23) in the USA
and Europe. This vaccine contains purified capsular antigens from
23 serotypes that cover 85% to 90% of cases of invasive pneu-
mococcal disease among adults (ERS 2014). The vaccine induces
T-cell-independent short-lived B-cell immune responses by caus-
ing B cells to differentiate into plasma cells, producing antibodies
without producing memory B cells. The immunological antibody
response is age- and serotype-dependent and generally is lower
among elderly people than in younger adults. A booster vaccina-
tion produces no memory response.
To enhance the immunogenicity of pneumococcal vaccines, re-
searchers have developed conjugate vaccines. Polysaccharide anti-
gens are chemically joined to a highly immunogenic protein car-
rier (such as tetanus or diphtheria toxoid). This process leads to
the induction of B cell-dependent and T cell-dependent responses
as well as a memory response to a booster dose of the vaccine.
Healthcare providers have administered pneumococcal conjugate
vaccine containing capsular polysaccharides from seven pneumo-
coccal serotypes (PCV-7) to young children since the 2000s, with a
resulting striking decrease in invasive pneumococcal disease caused
by vaccine serotypes. As children are the main reservoir of S pneu-
moniae (60% are carriers), a reduction in the carrier rate has had
beneficial effects among children and a protective herd effect in
adults (Moseley 2013).
Investigators are evaluating new conjugate vaccines, including 7-
valent (PCV-7), 10-valent (PCV-10) and13-valent (PCV-13) vac-
cines, for use in children and adults, although respiratory guide-
lines in Europe (ERS 2014) and Australia (COPDX 2016) rec-
ommend immunisation with the PPV-23 polysaccharide pneu-
mococcal vaccine for adults at risk of pneumococcal disease, in-
cluding those with COPD. The PCV-13 and the PCV-10 are not
recommended for patients with COPD in Australia (NHMRC
2013). Recommendations for age at immunisation and at revacci-
nation vary depending on the guideline, with some recommend-
ing vaccination only for patients who are over 64 years of age, or
for younger patients with severe COPD or comorbid conditions
(GOLD 2016), and others recommending vaccination for all pa-
tients 50 years of age and older, along with revaccination five years
later (NHMRC 2013).
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How the intervention might work
Patients with COPD are able to mount a significant immune re-
sponse to pneumococcal infection (Bogaert 2004); thus immu-
nisation against pneumococcal infection may be effective in pre-
venting bacterial growth in the airways of patients with COPD, in
turn decreasing the occurrence of exacerbations and pneumonia.
Why it is important to do this review
Major COPD guidelines (COPDX 2016; ERS 2014; GOLD
2016; NICE 2010) have recommended pneumococcal vaccina-
tion, largely on the basis of results showing the efficacy of pneumo-
coccal vaccination as reported by observational studies in general
populations and by randomised controlled trials (RCTs) in people
without COPD. Both a large indirect cohort study (Butler 1993)
and ameta-analysis (Fine 1994) of pneumococcal vaccination have
confirmed protection against invasive bacteraemic disease, but ef-
ficacy remains to be assessed in the population with COPD, for
which risks of CAP and of deterioration may be higher owing to
exacerbations of the disease.
O B J E C T I V E S
To determine the efficacy of injectable pneumococcal vaccination
for preventing pneumonia in persons with COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included in this review only RCTs using injectable pneumo-
coccal vaccines.
Types of participants
We included studies if participants were adults with a diagnosis of
COPD, preferably based on objective diagnostic criteria: demon-
stration of airflow obstruction on spirometry, generally forced ex-
piratory volume in one second (FEV1)/forced vital capacity (FVC)
ratio less than 0.7 (GOLD 2016) and a significant smoking his-
tory. We included studies in which the proportion of participants
with COPD was at least 80%, if the age of other participants
matched that of participants with COPD.
Types of interventions
At least one injectable pneumococcal vaccine - a pneumococcal
polysaccharide vaccine or a pneumococcal conjugate vaccine or
other vaccine type. The control group could be given placebo or
no vaccination, or different types of pneumococcal vaccine for
comparison.
Types of outcome measures
Primary outcomes
1. Pneumonia
2. Mortality, respiratory-related and all-cause
3. Healthcare utilisation, including hospital admissions and
emergency department visits
Secondary outcomes
1. Acute exacerbations of COPD
2. Days of disability from respiratory illness variously defined
as days in bed, days off work or days when the participant was
unable to undertake normal activities
3. Lung function
4. Adverse effects of vaccination
5. Cost-effectiveness of pneumococcal vaccination
6. Quality of life
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Specialised Register up to 25
November 2016. The Information Specialist for the Group main-
tains the Cochrane Airways Specialised Register, which contains
studies identified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (CRSO) (http://crso.cochrane.org/).
2. Weekly searches of MEDLINE Ovid SP.
3. Weekly searches of Embase Ovid SP.
4. Monthly searches of PsycINFO Ovid SP.
5. Monthly searches of the Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
We identified studies included in the Trials Register by applying
search strategies based on the scope of the Cochrane Airways Re-
view Group. We have provided details of these strategies, as well
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as a list of handsearched conference proceedings, in Appendix 1.
See Appendix 2 for search terms used to identify studies for this
review.
We carried out additional searches of CENTRALCRSO (searched
25 November 2016), MEDLINE Ovid (1946 to 23 November
2016) and Embase Ovid (1974 to 23 November 2016). We have
listed in Appendix 3 the search strategies used for these databases.
We applied no restrictions on language of publication.
Searching other resources
From full-text papers obtained, we searched the bibliographic lists
for additional articles. We also conducted a search of Clinical-
Trials.gov (www.ClinicalTrials.gov) and the World Health Or-
ganization (WHO) trials portal (www.who.int/ictrp/en/) up to
25 November 2016 and pharmaceutical company clinical trial
databases of companies manufacturing pneumococcal vaccines.
Data collection and analysis
Selection of studies
At least two review authors (JW, JT or RWB) assessed all poten-
tially relevant trials for relevance by screening the full texts to inde-
pendently select studies for inclusion and identified and recorded
reasons for exclusion of ineligible studies. We resolved disagree-
ments through discussion or, if required, we consulted a third re-
view author. We identified and excluded duplicates and collated
multiple reports of the same study, so that each study (rather than
each report) was the unit of interest in the review. We recorded
the selection process via a PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow diagram (Figure 2).
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Figure 2. Study flow diagram.
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Data extraction and management
Two review authors (JT, JW) independently extracted study details
and used a data collection form to record the following study
characteristics and outcome data.
1. Methods: study design, total duration of study, number of
study centres and locations, study setting, duration and date of
study.
2. Participants: N, mean age, age range, gender, withdrawals,
inclusion criteria and exclusion criteria.
3. Interventions: study treatment, comparison,
cointerventions.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, trial registration, notable conflicts
of interest of trial authors.
The first review author entered data into ReviewManager (version
5.3) (RevMan 2014), and a second review author double-checked
the data. We checked that data were entered correctly by compar-
ing data presented in the systematic review against information
provided in the study reports.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each
study (JW, JT), using criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Cochrane Handbook). We
resolved disagreements by discussion or by consultation with an-
other review author. We assessed risk of bias according to the fol-
lowing domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias(es).
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report, together with a jus-
tification for our judgement, in the ’Risk of bias’ table. We sum-
marised risk of bias judgements across different studies for each of
the domains listed. When information on risk of bias was related
to unpublished data or correspondence with a trialist, we noted
this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to those outcomes.
Measures of treatment effect
We analysed dichotomous outcomes by using Mantel-Haenszel
odds ratios (ORs) with 95% confidence intervals (CIs). When
events were rare, we employed the Peto odds ratio. We entered
scale data with a consistent direction of effect.
For continuous variables, we analysed data as mean differences
(MDs) with 95% CIs. We used standardised mean differences
(SMDs) with 95% CIs if investigators had used different scales of
measurement for a specific outcome. The SMD is a statistic that
expresses differences in means between treatment groups in units
of the pooled standard deviation.
We undertook meta-analyses only when this was meaningful, that
is, when treatments, participants and the underlying clinical ques-
tion were similar.
When skewed data were available (reported as medians and in-
terquartile ranges), we described them narratively.
For ’time-to-event’ outcomes such as log hazard ratios, we used
the fixed-effect generic inverse variance outcome to combine re-
sults. This method yields a weighted average of effect estimates of
separate studies (Cochrane Handbook, Chapter 9). We calculated
the number needed to treat for an additional beneficial outcome
from the pooled OR and its CI, using baseline risk in the control
group.
Unit of analysis issues
We used participants as the unit of analysis when analysing di-
chotomous data.
Dealing with missing data
We contacted investigators to obtain missing numerical outcome
data when possible (e.g. when a study was identified as abstract
only).
When this was not possible, and missing data were thought to
introduce serious bias, we explored the impact of including such
studies in the overall assessment of results by performing a sensi-
tivity analysis.
Assessment of heterogeneity
We used a Breslow-Day test to assess heterogeneity for pooled ef-
fects when the null hypothesis was that all studies were evaluating
the same effect; we considered a P value > 0.05 to indicate signif-
icant differences between studies.
In addition, we used the I2 statistic, which describes the percentage
of total variation across studies that is due to heterogeneity rather
than to chance (Higgins 2003). We interpreted statistical hetero-
geneity as follows: 0% to 40% might not be important, 30% to
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60%may represent moderate heterogeneity and 50% to 90%may
represent substantial heterogeneity (Cochrane Handbook).
We assessed clinical and methodological heterogeneity by record-
ing differences in study design and participant characteristics be-
tween individual studies. When we found substantial heterogene-
ity. we reported this and explored possible causes by conducting
prespecified subgroup analyses.
Assessment of reporting biases
We tried to minimise reporting bias resulting from non-publica-
tion of studies or from selective outcome reporting by using a
broad search strategy, checking references of included studies and
relevant systematic reviews and contacting study authors to ask
for additional outcome data. We visually inspected funnel plots
when 10 or more studies contributed to the analysis for a specific
outcome.
Data synthesis
We combined studies to compare the following.
1. Comparison 1: pneumococcal polysaccharide vaccine, 23-
valent (PPSV-23) OR 14-valent (PPV-14), versus control.
2. Comparison 2: 23-valent pneumococcal polysaccharide
vaccine (PPV-23) versus 7-valent diphtheria-conjugated
pneumococcal polysaccharide vaccine (PCV-7).
We used a fixed-effect model, but we performed a sensitivity anal-
ysis by using a random-effects model if we detected unexplained
heterogeneity.We presented the findings of our primary outcomes
in a ’Summary of findings’ table according to recommendations
provided in theCochrane Handbook for Systematic Reviews of Inter-
ventions (Cochrane Handbook) (generated with the use of Grade-
Pro software).
Subgroup analysis and investigation of heterogeneity
If heterogeneitywas not sufficiently accounted for by study quality,
we specified the following subgroup analyses a priori.
1. Vaccine type - the number of capsular polysaccharide
antigens used in the vaccine (more than 14 vs 14 or fewer).
2. Severity of COPD (assessed by lung function: mild = FEV1
50% to 79% predicted, moderate = FEV1 35% to 49%
predicted, severe = FEV1< 35% predicted).
3. Setting of the study.
4. Match between strain of vaccine and infecting strains.
5. Age of participants.
Sensitivity analysis
In assessing heterogeneity, we considered possible causes associated
with details of study design.
We performed sensitivity analyses using random-effects models
versus a fixed-effect model to examine risk of bias and other po-
tential confounders, and to evaluate studies published only as ab-
stracts.
R E S U L T S
Description of studies
Results of the search
From searches for the original 2004 review, we included two stud-
ies (Davis 1987; Leech 1987), and in 2010, we included five addi-
tional studies (Alfageme 2006; Furumoto 2008; Steentoft 2006;
Teramoto 2007 (published conference abstract); Ya Tseimakh
2006 (published conference abstract)). Through searches con-
ducted for this 2016 review (current to 25 November 2016)
(Figure 2), we identified 157 unique new citations, assessed 20 for
eligibility, and added five to this review (Dransfield 2009; Kostinov
2014; Lin 2013; Trofimov 2010 (published conference abstract);
Yilmaz 2013).
We have listed the reasons for exclusion of studies in the
Characteristics of excluded studies table.
Included studies
For specific details of each study included in the review, see the
Characteristics of included studies table.
We included in this review 12 RCTs of pneumococcal vaccines
for a total of 2171 participants that provided outcome data for
COPD.When studies included participants with other diagnoses,
such as Furumoto 2008, we included only data for participants
with COPD. Average duration of follow-up was 14 months. Two
studies (Steentoft 2006; Trofimov 2010) reported follow-up for
six months; three studies (Kostinov 2014; Lin 2013; Ya Tseimakh
2006) follow-up for 12 months; four studies (Furumoto 2008;
Leech 1987; Teramoto 2007; Yilmaz 2013) follow-up for 24
months; two studies (Alfageme 2006; Davis 1987) follow-up for
32 months and one study (Dransfield 2009) follow-up for 48
months.
Study setting and participants
All studies were conducted in a community setting and were ran-
domised, parallel-group trials (Table 1). Participants (n = 2171)
had a diagnosis of COPD that was based on spirometric crite-
ria (Alfageme 2006; Dransfield 2009; Kostinov 2014; Steentoft
2006);clinical or spirometric criteria (Davis 1987); a clinical di-
agnosis of COPD (Furumoto 2008; Lin 2013; Teramoto 2007;
Ya Tseimakh 2006; Yilmaz 2013); or a diagnosis not specified
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(Trofimov 2010). A common exclusion criterion was previous
pneumococcal vaccination. The average age of study partici-
pants was 66 years, and the percentage of male participants was
67%(range 36% to 98%). When data could be extracted, the
mean FEV1 was 1.2 L (five studies), 54% of predicted (four stud-
ies). Information on participants’ treatment with inhaled corti-
costeroids was available only for Dransfield 2009 (65%) and Lin
2013 (100%); in Steentoft 2006, 24% of participants were taking
oral corticosteroids.
Intervention and comparison
Vaccine type
Investigators used a 23-valent pneumococcal polysaccharide vac-
cine in Alfageme 2006, Dransfield 2009, Kostinov 2014, Lin
2013, Steentoft 2006, Teramoto 2007, Trofimov 2010, Ya
Tseimakh 2006 and Yilmaz 2013, and a 14-valent pneumococcal
polysaccharide vaccine in Davis 1987, Furumoto 2008 and Leech
1987.
Treatment groups in Leech 1987 and Furumoto 2008 also received
influenza vaccine.
Comparison
Control groups in Leech 1987 and Furumoto 2008 received the
same influenza vaccine as the intervention group.
Control groups inDavis 1987, Lin 2013 andYilmaz 2013 received
a placebo injection.
Researchers in Alfageme 2006, Kostinov 2014, Steentoft 2006,
Teramoto 2007, Trofimov 2010 and Ya Tseimakh 2006, withheld
vaccine from the control group and did not administer a placebo.
Dransfield 2009 used a different vaccine in the comparison group
- a 7-valent diphtheria-conjugated pneumococcal polysaccharide
vaccine.
In all studies, investigators administered injections subcuta-
neously.
Outcome measurement
Eight studies reported data on participants experiencing one or
more episodes of pneumonia - but not all episodes were con-
firmed as due to pneumococcal infection (Alfageme 2006; Davis
1987; Dransfield 2009; Furumoto 2008; Leech 1987; Lin 2013;
Steentoft 2006; Teramoto 2007). The basis for the diagnosis of
pneumonia was radiological AND included clinical symptoms/
signs in Alfageme 2006, Davis 1987, Leech 1987 and Steentoft
2006; was radiological OR included clinical symptoms/signs in
Furumoto 2008 and Lin 2013; and was self-reported by partici-
pants in Dransfield 2009.
Excluded studies
Of 100 excluded citations, 35 were reviews/commentary articles,
41 were not of RCT design, 18 included non-COPD participants
or did not provide their data separately and six provided an inter-
vention that was not an injectable pneumococcal vaccine. Individ-
ual reasons for exclusion of studies are listed in the Characteristics
of excluded studies table.
Risk of bias in included studies
Review authors assessed the quality of the 12 studies included in
the review against six criteria and provide a summary of results in
Figure 3 and Figure 4.
12Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 4. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Allocation generation
Overall risk of selection bias due to allocation generationwasmod-
erate. Six of the 12 studies did not report their methods for ran-
dom sequence generation (Leech 1987; Lin 2013; Teramoto 2007;
Trofimov 2010; Ya Tseimakh 2006; Yilmaz 2013). All of the re-
maining trials had low risk of bias. Methods for random sequence
generation varied by study. Four studies used random number ta-
bles, one performed random number generation in blocks of 10
(Alfageme 2006) and another conducted randomisation centrally
online (Dransfield 2009).
Allocation concealment
Overall risk of selection bias due to allocation concealment was
moderate. However, nine of the 12 studies did not report their
methods for allocation concealment (Alfageme 2006; Davis 1987;
Kostinov 2014; Leech 1987; Lin 2013; Teramoto 2007; Trofimov
2010; Ya Tseimakh 2006; Yilmaz 2013). The remaining three had
low risk of bias. Allocation concealment methods included third
party randomisation and sequentially numbered, opaque, sealed
envelopes.
Blinding
Overall risk of performance bias and detection bias was moderate,
with three studies at particularly high risk of bias (Furumoto 2008;
Trofimov 2010; Ya Tseimakh 2006). Two had low risk of bias
(Alfageme 2006; Davis 1987), and nine could not be adequately
assessed for risk.
Of the 12 studies, two were double-blind (Davis 1987; Leech
1987), three were single-blind (Alfageme 2006; Leech 1987;
Yilmaz 2013), two were open-label (Dransfield 2009; Trofimov
2010) and five did not describe the use of blinding. Among dou-
ble-blind trials, only Davis 1987 adequately described the method
of blinding used. Of three single-blind trials, Leech 1987 blinded
participants, Alfageme 2006 blinded assessors and Yilmaz 2013
did not indicate who was blinded. We could not perform sensi-
tivity analysis for Dransfield 2009, as it was the only study that
compared PPSV-23 versus PCV-7. However, sensitivity analysis
for the outcome of acute COPD exacerbation for Trofimov 2010
showed little change in the direction of effect.
Six of the 12 studies (Alfageme 2006; Kostinov 2014; Steentoft
2006; Teramoto 2007; Trofimov 2010; Ya Tseimakh 2006) did
not use any form of placebo; Dransfield 2009 used PCV-7 as a
comparator. Sensitivity analysis for the primary outcome of pneu-
monia with exclusion of these studies showed a shift in effect direc-
tion, although the OR remained of no statistical significance (OR
0.78, 95% CI 0.16 to 3.68). For acute exacerbations of COPD,
data showed no shift in effect direction nor in OR significance,
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with a wider CI (OR 0.41, 95% CI 0.18 to 0.92). We noted sim-
ilar findings for all-cause mortality (OR 0.95, 95% CI 0.48 to
1.86) and all-cause hospital admissions (OR 0.80, 95% CI 0.21
to 3.13).
Incomplete outcome data
Overall risk of attrition bias was low. Six of the 12 studies managed
to adequately address incomplete outcomes, with no unequal rates
across groups and with adequate reasons provided for drop-outs
and losses to follow-up (Alfageme 2006; Davis 1987; Dransfield
2009; Furumoto 2008; Kostinov 2014; Lin 2013).
Selective reporting
Overall risk of reporting bias was very low. Nine of the 12 stud-
ies adequately addressed all primary and secondary outcomes
(Alfageme 2006; Davis 1987; Dransfield 2009; Furumoto 2008;
Kostinov 2014; Leech 1987; Lin 2013; Steentoft 2006; Yilmaz
2013).
Other potential sources of bias
Of the 12 studies, 11 did not display other types of bias (Alfageme
2006; Davis 1987; Furumoto 2008; Kostinov 2014; Leech 1987;
Lin 2013; Steentoft 2006; Teramoto 2007; Trofimov 2010; Ya
Tseimakh 2006; Yilmaz 2013). The only study that displayed un-
clear risk was Dransfield 2009. As this study relied in part on self-
reported vaccination, some participants may have been misclassi-
fied as vaccine-naive or previously vaccinated; or may have been
enrolled within five years after the previous vaccination dose.
Effects of interventions
See: Summary of findings for the main comparison
Pneumoccocal vaccination to prevent pneumonia in chronic
obstructive pulmonary disease?
Comparison 1: pneumococcal polysaccharide vaccine,
23-valent (PPSV-23) OR 14-valent (PPV-14), versus
control (11 studies; N = 2125)
Primary outcomes
Pneumonia
Analysis 1.1: likelihood of at least one episode of community-
acquired pneumonia (CAP): We found six relevant studies (n =
1372) with follow-up ranging from six to 36 months. Results
showed a statistically significant difference with lower likelihood
for vaccine comparedwith control (subgroupedby vaccine number
of serotypes) (OR 0.62, 95% 0.43 to 0.89) and no heterogeneity (
Figure 5). Subgroup analysis of likelihood of CAPby lung function
was possible only with data from Alfageme 2006 (Analysis 3.1)
for participants with FEV1 < 40% predicted at baseline (OR 0.48,
95% CI 0.23 to 1.00) and for participants with FEV1 ≥ 40%
predicted (OR 1.12, 95% CI 0.50 to 2.48). A test for subgroup
differences was not statistically significant: Chi² = 2.36, df = 1 (P
= 0.12), I² = 57.6%.
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Figure 5. Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 Community-
acquired pneumonia: at least 1 episode.
Analysis 1.2: rate of CAP per person-year: For this outcome, we
found one relevant trial with 12 months of follow up (n = 36).
Investigators reported no significant differences between vaccine
and control groups (risk ratio (RR) 0.37, 95% CI 0.12 to 1.14).
Analysis 1.3: likelihood of at least one episode of pneumococcal
pneumonia: We found three relevant trials with follow-up ranging
from six to 36 months (n = 1158). Results showed no significant
differences between vaccine and control groups (subgrouped by
vaccine number of serotypes) (Peto OR 0.26, 95% CI 0.05 to
1.31) (Figure 6). Heterogeneity was substantial: Chi² = 3.44, df
= 1 (P = 0.06), I² = 71%; and the test for subgroup differences
approached significance:Chi² =3.44, df = 1 (P = 0.06), I² = 70.9%.
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Figure 6. Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.4 Death from
cardiorespiratory causes.
Mortality
Analysis 1.4: death from cardiorespiratory causes: We found three
relevant studies, with follow-up ranging from 24 to 48 months (n
= 888). Results showed no significant differences in likelihood be-
tween vaccine and control groups (subgrouped by vaccine number
of serotypes) (OR 1.07, 95%CI 0.69 to 1.66) (Figure 6) and no
heterogeneity.
Analysis 1.5: death from all causes: We found five relevant trials
with follow-up ranging from 12 to 48 months (n = 1053). Results
revealed no significant differences in likelihood between vaccine
and control groups (subgrouped by vaccine number of serotypes)
(OR 1.00, 95% CI 0.72 to 1.40) and no heterogeneity.
Healthcare utilisation
Analysis 1.6: likelihood of at least one episode of hospital admis-
sion for any cause: We found three relevant studies with follow-
up ranging from three to 12 months (n = 391). Results showed no
significant differences in likelihood between vaccine and control
groups (OR 0.74, 95% CI 0.32 to 1.74) and no heterogeneity.
When we included the 24-month follow-up period for Yilmaz
2013, which was affected by a greater number of withdrawals
(Analysis 3.2), the result was similar (OR 0.54, 95% 0.23 to 1.22).
Analysis 1.7: rate of cardiorespiratory-related hospital admissions:
We found one relevant study (Leech 1987; n = 160) that reported
no significant differences between vaccine and control groups for
follow-up between seven and 12 months (RR 0.89, 95% CI 0.51
to 1.58) nor any differences for longer follow-up periods of 13 to
18 months and 19 to 24 months (Analysis 3.3).
Analysis 1.8: rate of all-cause hospital admissions: We found one
relevant study with 12 months of follow-up (n = 36). Results
showed no significant differences between vaccine and control
groups (RR 0.84, 95% CI 0.26 to 2.71).
Analysis 1.9: likelihoodof at least one emergency department (ED)
visit for any cause: We found one relevant study (Yilmaz 2013)
with follow-up between three and 12 months (n = 142). Results
showed statistically significant differences, with lower likelihood
for vaccine compared with control (OR 0.26, 95% CI 0.07 to
0.91); results for a long-term follow-up period of 12 to 24 months
were similar (Analysis 3.4). Another single study (Leech 1987) re-
ported ED visits due to respiratory causes, upper respiratory tract
infection (URTI), lower respiratory tract infection (LRTI) and
pneumonia and described no significant differences with vaccina-
tion (Analysis 3.5).
Secondary outcomes
Analysis 1.10: likelihood of at least one episode of COPD exac-
erbation: For this outcome, we found four relevant studies (n =
446), with varyingdurations of follow-up: sixmonths for Steentoft
2006, 12 months for Kostinov 2014 and Yilmaz 2013 and 24
months for Furumoto 2008. Results showed a statistically signifi-
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cant difference with lower likelihood for vaccine than for control
(OR 0.60, 95% CI 0.39 to 0.93) (Figure 7 and Figure 1), with
no heterogeneity. When we used the 24-month follow-up period
for Yilmaz 2013, which was affected by a greater number of with-
drawals, the result was similar (Analysis 3.6) but showed greater
heterogeneity (OR 0.53, 95% CI0.34 to 0.81; Chi² = 5.66, df =
3 (P = 0.13), I² = 47%).
Figure 7. Forest plot of comparison: 1 Pneumococcal vaccine versus control, outcome: 1.1 At least 1 COPD
exacerbation.
Analysis 1.11: COPD exacerbations: For this outcome, we found
one relevant study with six months of follow-up (n = 373). Results
showed a significant difference between vaccine and control groups
(mean difference (MD) -0.59 episodes, 95% CI -0.80 to -0.38).
Analysis 1.12: rate of COPD exacerbations per person-year: For
this outcome, we found one relevant study with 12 months of fol-
low-up (n = 36). Results showed no significant differences between
vaccine and control groups (RR 0.87, 95% CI 0.44 to 1.72).
Lung function
Analysis 1.13: FEV1: We found one relevant study with follow-up
of 24 months (n = 144). Results showed no significant differences
between vaccine and control groups for measurements taken at
three, 12 and 24 months.
Health-related quality of life
Analysis 1.14: St George’s Respiratory Questionnaire (SGRQ)
overall score: We found one relevant study with follow-up of 24
months (n = 144). Results showed no significant differences be-
tween vaccine and control groups for measurements taken at three,
12 and 24 months.
Adverse effects
No data were available for meta-analysis. Adverse effects reported
after vaccination in Ya Tseimakh 2006 included erythema and
induration observed in 22% and fever and headache in 5%.
Leech 1987 stated that “there were no adverse reactions to pneu-
mococcal vaccine”, and study authors for Alfageme 2006 indi-
cated that “no patient reported any local or systemic reaction to
the vaccine”.
Sensitivity analysis
In sensitivity analysis of the likelihood of community-acquired
pneumonia with removal of studies available only as conference
abstracts, and with Teramoto 2007 and Ya Tseimakh 2006 ex-
cluded, effect size was lessened and became non-significant and
18Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
heterogeneity was eliminated, although the direction of effect re-
mained the same (OR 0.80, 95% CI 0.51 to 1.25; four studies, n
= 803).
Comparison 2: 23-valent pneumococcal
polysaccharide vaccine (PPV-23) versus 7-valent
diphtheria-conjugated pneumococcal polysaccharide
vaccine (PCV-7); (one study; N = 181)
Only one study (n = 181) compared 23-valent pneumococcal
polysaccharide vaccine (PPSV-23) with 7-valent diptheria-conju-
gated pneumococcal polysaccharide vaccine (PCV-7) (Dransfield
2009). The follow-up period was 48 months. This study found no
statistically significant differences in likelihood between the two
vaccines in terms of:
1. Analysis 2.1: incidence of community-acquired pneumonia
(OR 1.01, 95% CI 0.40 to 2.56);
2. Analysis 2.2: all-cause mortality (OR 1.83, 95% CI 0.5 to
6.50);
3. Analysis 2.3: hospital admission (OR 0.91, 95% CI 0.47 to
1.74); and
4. Analysis 2.4: COPD exacerbation (OR 1.07, 95% CI 0.60
to 1.91).
We assessed short-term adverse effects of vaccines by using a seven-
day diary (Analysis 2.5) and noted a statistically significant differ-
ence for PPSV-23 compared with PCV-7 in the likelihood of fa-
tigue (OR 2.40, 95% CI 1.15 to 5.00) and redness or discoloura-
tion ≤ 15 cm (OR 3.52, 95% CI 1.51 to 8.21).
We found no statistically significant differences for PPSV-23 com-
pared with PCV-7 in the likelihood of headache (OR 1.59, 95%
CI 0.61 to 4.18), fever (OR 0.66, 95% CI 0.14 to 3.10), pain
(OR 1.36, 95% CI 0.66 to 2.82), localised swelling (OR 1.61,
95% CI 0.74 to 3.52), limitation in arm movement (OR 1.85,
95% CI 0.88 to 3.90) or redness or discolouration > 15 cm (OR
4.67, 95% CI 0.22 to 99.46).
D I S C U S S I O N
Summary of main results
For this systematic review update, a total of 12 randomised con-
trolled trials (RCTs) (2171 participants) met our inclusion crite-
ria. These investigators reported the effects of injectable pneumo-
coccal polysaccharide vaccines (PPVs) in 2171 participants with
chronic obstructive pulmonary disease (COPD).When compared
with control for the primary outcome - protection against com-
munity-acquired pneumonia (CAP) - results showed a lower like-
lihood with vaccine (odds ratio (OR) 0.62, 95% confidence inter-
val (CI) 0.43 to 0.89; GRADE: moderate). The number needed
to treat for an additional beneficial outcome (NNTB) to prevent
one episode of CAP was 21 (95% CI 15 to 74). However, for
pneumococcal pneumonia, researchers reported no significant dif-
ference with vaccination (Peto OR 0.26, 95% CI 0.05 to 1.31;
GRADE: low), with only three studies (Alfageme 2006; Leech
1987; Ya Tseimakh 2006) measuring events and observing very
few events. The difference in results between CAP and pneumo-
coccal pneumonia may be related to both the paucity of events
and non-detection of pneumococcus.
We found no difference in mortality from cardiorespiratory causes
between vaccine and control (OR 1.07, 95% CI 0.69 to 1.66;
GRADE: moderate) in three studies (Alfageme 2006; Davis 1987;
Leech 1987), nor in all-cause mortality in five studies (Alfageme
2006; Davis 1987; Leech 1987; Lin 2013; Yilmaz 2013) (OR
1.00, 95% CI 0.72 to 1.40; GRADE: moderate).
The likelihood of hospital admission for any cause or for cardiores-
piratory causes did not differ between vaccine and control groups;
three studies reported admission for all causes (Kostinov 2014;
Steentoft 2006; Yilmaz 2013) (OR 0.74, 95% CI 0.32 to 1.74;
GRADE: moderate), and one study for cardiorespiratory-related
causes (Leech 1987) (risk ratio (RR) 0.89, 95% CI 0.51 to 1.58;
GRADE: moderate). The likelihood of an emergency department
visit for any cause was lower in one study (Yilmaz 2013) for vac-
cine than for control (OR 0.26, 95% CI 0.07 to 0.91; GRADE:
moderate).
The likelihood of a COPD exacerbation (Figure 7) was signifi-
cantly reduced (OR 0.60, 95% CI 0.39 to 0.93; GRADE: mod-
erate) in four studies (Furumoto 2008; Kostinov 2014; Steentoft
2006; Yilmaz 2013). The NNTB to prevent one episode of acute
exacerbation was 8 (95% CI 5 to 58), which represents a reduc-
tion in risk from 608/1000 for control to 482/1000 for vaccina-
tion (Figure 1). Three of these studies defined exacerbations of
COPD as worsening respiratory symptoms beyond normal day-
to-day variation, and the basis for exacerbations was not given in
Kostinov 2014, as the definition was not based on any need for
additional treatment, and we were not able to classify the severity
of the exacerbations. Ya Tseimakh 2006 provided no definition
of an exacerbation (published abstract only) and reported a lower
exacerbation rate over six months (Analysis 1.11; mean difference
(MD) -0.59, 95% CI -0.80 to -0.38). The rate of exacerbation in
Lin 2013 was not lower with vaccination; this study assessed the
effect of vaccination on moderate exacerbations of COPD (Burge
2003), defined as the requirement for treatment with parenteral
corticosteroids with or without an antibiotic (Analysis 1.12; RR
0.87, 95% CI 0.44 to 1.72).
One study (Ya Tseimakh 2006) reported local adverse effects in
the vaccination group only, with erythema occurring in 22% of
vaccinated participants. Another study (Alfageme 2006) found no
significant difference in lung function between vaccine and control
groups.
No studies provided data on days of disability from respiratory
illness or cost-effectiveness of pneumococcal vaccination for meta-
analyses comparing vaccine and control.
A single study (Dransfield 2009) comparing 23-valent pneumo-
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coccal polysaccharide vaccine and 7-valent pneumococcal conju-
gate vaccine reported no differences in vaccination outcomes for
CAP (OR 1.01, 95% CI 0.40 to 2.56), for mortality from all
causes (OR 1.83, 95% CI 0.5 to 6.50), for hospital admission for
any cause (OR 0.91, 95% CI 0.47 to 1.74) or for likelihood of
experiencing a COPD exacerbation (OR 1.05, 95% CI 0.58 to
1.88). The likelihood of somemild adverse effects was higher with
vaccination, with increased likelihood for PPV-23 compared with
PCV-7 for fatigue (OR 2.40, 95% CI 1.15 to 5.00), local redness
or discolouration ≤ 15 cm (OR 3.52, 95% CI 1.51 to 8.21) and
limitation of arm movement (OR 1.85, 95% CI 0.88 to 3.90).
Overall completeness and applicability of
evidence
Some studies described gender imbalance among participants;
three studies includedmore than80%male participants (Alfageme
2006; Lin 2013; Yilmaz 2013). Cigarette smoking is recognised
as the single biggest risk factor in the development of COPD, and
in some studies, gender imbalance reflects the imbalance among
smokers or among participants treated in veterans’ healthcare fa-
cilities. We examined studies for differences in baseline charac-
teristics that might potentially confound results. Baseline forced
expiratory volume in one second (FEV1) and FEV1/forced vital
capacity (FVC) did not significantly differ across groups in all fully
published studies nor in studies for which study authors supplied
data. Influenza vaccination was similar in Furumoto 2008 (100%
vaccination and control) and Yilmaz 2013 (62% vaccination, 52%
control) - two studies that contributed to analysis of COPD exac-
erbations, but Kostinov 2014 and Steentoft 2006 did not report
influenza vaccine status.
Treatments given in control groups varied. In Furumoto 2008 and
Leech 1987, intervention groups received both a pneumococcal
polysaccharide vaccine and an influenza vaccine, and the control
group received only the influenza vaccine. In Alfageme 2006,
Kostinov 2014, Steentoft 2006,Teramoto 2007, Trofimov 2010
and Ya Tseimakh 2006, control groups did not receive a vaccine.
Analysis by severity of COPD showed no significantly different
effects for risk of pneumonia for severe compared with moderate
airflow limitation.
Results may be compared with those reported by RCTs that did
not provide separate data for participants with COPD. In several
older studies, for example, Klastersky 1986, in which participants
had bronchogenic carcinoma, investigators found a small advan-
tage for vaccination regarding likelihood of pneumococcal infec-
tion, Gaillat 1985 found a lower likelihood of pneumonia but
no effect on mortality among residents living in aged-care facili-
ties and Koivula 1997 found no reduction in pneumonia events
overall but a protective effect of pneumococcal vaccination in per-
sons at increased risk of pneumonia (age≥ 70 years, heart disease,
lung disease, bronchial asthma, alcoholism, institutionalised or
permanently bedridden). Simberkoff 1986 showed no difference
in pneumonia among high-risk participants (age > 55, chronic re-
nal, hepatic, cardiac or pulmonary disease; alcoholism; or diabetes
mellitus). Ortqvist 1998, which included 21% of participants 50
to 85 years of age with COPD, found no reduction in risk of pneu-
monia, pneumococcal pneumonia or mortality with vaccination
compared with placebo.
A recent large study (Bonten 2015) compared 13-valent pneu-
mococcal conjugate vaccine versus placebo in 84,496 participants
over 65 years of age at 101 community-based sites in the Nether-
lands, where pneumococcal vaccination in older adults was not
routine. Risk of CAP in the PCV-13 group compared with the
placebo group was reduced by 37.7% (95% CI 14.3 to 55.1), and
risk of invasive pneumococcal disease was reduced by 75.8% (95%
CI 46.5 to 90.3) in modified intention-to-treat (ITT) analyses.
Results are not available for participants with COPD, but overall,
12.3% of participants were current smokers, 4.9% reported a di-
agnosis of asthma and 25.4% had been given a diagnosis of heart
disease.
A systematic review (Kew 2014) showed that people with COPD
treated with inhaled corticosteroids (budesonide and fluticasone,
delivered alone or in combination with a long-acting beta ago-
nist (LABA)) had increased risk of serious pneumonia resulting in
hospitalisation. In this current review of effects of pneumococcal
vaccines for preventing pneumonia, only three studies reported
the proportion of participants using corticosteroids; Lin 2013 in-
dicated that 100% of participants were taking inhaled corticos-
teroids, Steentoft 2006 revealed that 24% used oral corticosteroids
in the comparison with control and Dransfield 2009 described use
of inhaled corticosteroids by 65% of participants in comparisons
of PPV-23 versus PCV-7. Subgroup analyses were not possible.
Clinical guidelines provided by internationally recognised respi-
ratory societies have advocated use of pneumococcal vaccination
in patients with COPD. Guidelines from the UK National Insti-
tute of Clinical Excellence (NICE) state that “pneumococcal vac-
cination and an annual influenza vaccination should be offered
to all patients with COPD as recommended by the Chief Medi-
cal Officer” (NICE 2004). COPDX guidelines for Australia and
New Zealand state that “pneumococcal immunisation (polyvalent
covering 23 virulent serotypes) is recommended in people with
COPD”, and evidence for this recommendation is graded at level
II (COPDX 2016). TheGlobal Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines published jointly by the Na-
tional Heart Lung and Blood Institute in the USA and the World
Health Organization (WHO) advise that “pneumococcal vacci-
nation should be offered to every COPD patient; vaccine appears
to be more effective in older patients and those with more severe
disease or cardiac comorbidity” (GOLD 2016).
The WHO (WHO 2012) has made recommendations for use of
pneumococcal vaccines in children, which are influencing pneu-
mococcal disease, carriage and herd protection. Pneumococcal
conjugated vaccines PCV-10 and PCV-13 are licensed for preven-
tion of invasive disease, pneumonia and acute otitis media caused
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by respective vaccine serotypes in children from six weeks to five
years of age, with high vaccine efficacy. The WHO recommends
that inclusion of PCVs be given priority in childhood immunisa-
tion programmes worldwide, especially in countries with under-
five-mortality of > 50/1000 live births. Although herd effects of
immunisation in children have reduced invasive pneumococcal
disease (IPD), it is recommended that adults over 65 should be
immunised.
The studies included in this review reported a low frequency of
proven pneumococcal pneumonia; thus we acknowledge the pos-
sibility of a type 2 error, given the rare events reported. Investi-
gators have found that the overall contribution of pneumococcal
pneumonia to overall CAP varies (Rodrigo 2015); between 2008
and 2013, rates of 17.1% to 37.3% were reported.
A recent systematic review aimed to determine the incidence and
burden of vaccine-preventable pneumococcal disease in the adult
population in the UK (Chalmers 2016). This study found a high
burden of pneumococcal disease among adults, along with sub-
stantial ongoing changes in the epidemiology of pneumococcal
disease. Among those > 65 years of age, the incidence of IPD in
2013-2014 was 20.58 per 100,000 population. However, the in-
cidence of PCV13 serotype IPD among people > 65 years of age
was 10.33 per 100,000 population from 2008 to 2010, and fell
to 3.72 per 100,000 in 2013-2014. In this population, PCV-7
serotypes were reduced from 4.58 per 100,000 in 2008 to 2010
to 0.53 per 100,000 population in 2013-2014.
Quality of the evidence
We graded evidence showing beneficial effects on CAP (OR 0.62,
95% 0.43 to 0.89) and effects on mortality estimates (OR 1.07,
95% CI 0.69 to 1.66 for cardiorespiratory causes; OR 1.00, 95%
CI 0.72 to 1.40 for all-cause mortality) as havingmoderate quality.
We are moderately confident in the effect estimate: The true effect
is likely to be close to the estimate of effect butmay be substantially
different. We graded evidence for the unchanged likelihood of
hospital admission for any cause (OR 0.74, 95% CI 0.32 to 1.74)
as having moderate quality. We graded the quality of evidence
for the lower likelihood of an acute exacerbation of COPD (OR
0.25, 95% CI 0.16 to 0.38) as moderate; lack of participant and/
or personnel blinding may have led to better general care and
treatment for patients with COPD in the vaccinated group.
Potential biases in the review process
Methodological limitations
Twelve studies involving 2171 participants contributed data to this
review. At the review level, we believe incomplete identification of
studies was not an issue, and we found no evidence of publication
bias. The average number of participants per study was 187, al-
though individual studies reported from 36 to 600 participants;
these relatively low numbers are probably too small, given the in-
cidence of pneumococcal infection among study populations. It is
likely that larger studies with participant numbers of around 1000
would be needed to demonstrate statistically significant effects.
Agreements and disagreements with other
studies or reviews
A systematic review current to June 2012 (Moberley 2013) assessed
the efficacy and effectiveness of PPVs in preventing pneumococcal
disease or death among adults. In 18 RCTs involving 64,852 par-
ticipants, investigators provided strong evidence of PPV efficacy
against IPD (OR 0.26, 95% CI 0.14 to 0.45). They found effi-
cacy against all-cause pneumonia in low-income (OR 0.54, 95%
CI 0.43 to 0.67) but not in high-income countries among the
general population (OR 0.71, 95% CI 0.45 to 1.12) and among
adults with chronic illness (OR 0.93, 95%CI 0.73 to 1.19). Study
authors noted that vaccine efficacy against primary outcomes ap-
peared poorer among adults with chronic illness, but small num-
ber of identified studies limited power to detect significant effects.
This review also found no significant change in all-cause mortality
(OR 0.90, 95% CI 0.74 to 1.09).
Review authors have assessed evidence for effectiveness of pneu-
mococcal vaccine in other chronic respiratory conditions; a sys-
tematic review of children and adults with bronchiectasis, current
to November 2008, identified no eligible RCTs (Chang 2009). A
systematic review, current to May 2014, conducted to assess the
efficacy of pneumococcal vaccines in reducing morbidity among
peoplewith cystic fibrosis, also identifiedno relevant trials (Burgess
2014). A systematic review of the efficacy of pneumococcal vaccine
in reducing mortality or morbidity from pneumococcal disease
among patients with asthma (Sheikh 2002) found no evidence of
effects on acute asthma exacerbations.
Studies using a retrospective, case-control design that often in-
cluded people with chronic lung conditions showed the efficacy
of pneumococcal vaccination to be approximately 50% to 80%
against invasive pneumococcal disease in high-risk populations
(Fedson 1994; Leophonte 2001). Prospective cohort studies have
generally failed to show reductions in the risk of non-bacteraemic
infection, although Alfageme 2006 and Jackson 2003 demon-
strated protection against bacteraemia. Regardless of design, most
studies have found that the protective efficacy of vaccination is
uniformly diminished in elderly and immunocompromised indi-
viduals. Although cohort studies are potentially easier to conduct
logistically (Hak 2006), evidence from these studies is subject to
limitations in generalisability (Hak 2006) and in interpretation
(Jackson 2006).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence derived from RCTs included in this
review suggests that injectable polyvalent pneumococcal vaccines
provide protection against community-acquired pneumonia and
reduce the likelihood of exacerbations of chronic obstructive pul-
monary disease (COPD). Evidence was insufficient for compar-
isons of different pneumococcal vaccine types. Evidence in this re-
view supports pneumococcal vaccination for people with COPD,
as recommended by respiratory guidelines.
Implications for research
Pneumococcal immunisation among children and older adults
in many countries has reduced the incidence and changed the
epidemiology of pneumococcal disease. Future randomised con-
trolled trials restricted to people with COPD will be difficult to
conduct with adequate power to detect significant effects, espe-
cially for rare events such as confirmed pneumococcal pneumonia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfageme 2006
Methods Setting of study: population-based intervention
Study design: RCT parallel
Type of analysis: case available
Participants Total number of participants: 600 (4 lost to follow-up; 2 from each group)
Gender distribution: vaccine group M = 96.6%; control group M = 93.3%
Mean age (years): vaccine group = 69; control group = 68
Age range: vaccine group = 62 to 73; control group = 61 to 73
Inclusion criterion: spirometric diagnosis of COPD
Exclusion criteria: prior pneumococcal vaccination, pregnant, immunosuppressed,
known neoplasia, renal insufficiency in dialysis, HIV infection, hypogammaglobuli-
naemia, anatomical and/or functional asplenia
Diagnostic criteria (COPD): SEPAR criteria (Sociedad Espanola de Patologia Respirato-
ria, or Spanish Society of Respiratory Pathology), FEV1 < 80% and FEV1/FVC < 70%;
severity of COPD: vaccine group FEV1 < 40% = 132; ≥ 40% = 166; control group
FEV1 < 40% = 114; ≥ 40% = 184
Current smokers: vaccine group = 22%; control group = 26%
Diagnostic criteria (pneumonia): clinical symptoms (lower respiratory tract infection
with fever) and imaging findings (new infiltrate typical of pneumonia, which decreases
during follow-up). Pneumococcal pneumonia diagnosed with isolated S pneumoniae in
blood, pleural fluid or bronchial samples.
Microbiological diagnosis (pneumococcus): presence of pneumonia and isolation of S
pneumoniae from sputum, broncho-aspirate, blood, pleural fluid or CSF
Interventions Vaccine type: 23-valent pneumococcal capsular polysaccharide
Numbers in each group: intervention = 298; control (no intervention) = 298
Dose: 0.5 mL Pneumo-23, Sanofi-Pasteur MSD
Delivery: subcutaneous injection in deltoid muscle
Cointerventions: none
Comparison: no vaccine
Duration of study: vaccine group, median 980 days (range 20 to 1454); control group,
median 978 days (range 21 to 1183)
Outcomes Types of outcomes measured:
- Acute exacerbations: definition: (1) increased dyspnoea, (2) increased sputum volume
and (3) increased sputum purulence and (4) absence of newly appeared infiltration on a
chest radiograph; 2 of the 3 respiratory symptoms present, or 1 of
these and 1 additional symptom, such as fever with no other causes or increased cough;
I = 30, C = 9
- Pneumonia: definition: clinical symptoms (cough, sputum or fever) plus increased
white blood cell count or serum C-reactive protein and appearance of a new infiltration
on chest radiograph; pneumonia-free survival plot, log rank = 1.15, P = 0.28 (NS))
- Number of hospital admissions (yes, all causes): I = 18, C = 6
- Change in lung function: reported, but data cannot be used
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Alfageme 2006 (Continued)
- All-cause mortality in year post vaccination: no
Notes C = control, I = intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation code developed with a
computer random number generator in
block lengths of 20 (10 in each group)
Allocation concealment (selection bias) Unclear risk “They were then randomly assigned to the
intervention group”
Not stated if allocation was performed cen-
trally or with the use of sealed opaque en-
velopes
Blinding (performance bias and detection
bias)
Assessors
Low risk “The vaccination status of the patient was
kept in a specific encrypted database and
was not stated in the patients’ clinical
records. Themain investigator of this study
(IA) was the only person with access to this
database, but this investigator did not par-
ticipate in the follow-up or in adjudicat-
ing the outcome events. This task was per-
formed by the physicians conducting the
follow-up, who were unaware of the treat-
ment group allocation of their patients.
These investigators were committed not to
ask patients about their vaccination status.
”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding measures used in the study
“A considerable limitation of this study
is the lack of a blind placebo comparison
group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Four patients (2 from each arm of the
study) were lost to follow-up and were ex-
cluded from final analyses
A minimum follow-up period of 3 years
was given for each participant, except 115,
who died before the end of follow-up
Selective reporting (reporting bias) Low risk The study protocol was not available, but it
appears that published reports include the
prespecified outcomes
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Alfageme 2006 (Continued)
Other bias Low risk No other issues were noted.
Davis 1987
Methods Study design: randomised, double-blind, placebo-controlled trial
Methodof randomisation: randomnumber table. Participants studied for 1 to 48months
of treatment
Study outcomes assessed by person blinded to Tx allocation? yes
Participants Total number of participants: 103
Gender distribution: not stated
Mean age (years): intervention group = 64 ± 10, control group = 61 ± 10
Age range: not stated
Inclusion criterion: COPD (assessed by clinical and pulmonary function criteria)
Exclusion criteria:
- Reversible airflow obstruction in the absence of chronic bronchitis (cough 3 of 12
months for 3 consecutive years) or emphysema as judged clinically, radiologically and
by lung function testing
- Malignant neoplasms
- Sickle cell disease
- Severe renal impairment
- Severe hepatic impairment
Diagnostic criteria (COPD): ATS standards
Severity of COPD: active: FEV1 (L) = 1.33 ± 0.61; FEV1/FVC = 52 ± 13; placebo:
FEV1 (L) = 1.47 ± 0.75; FEV1/FVC = 55 ± 14
Smoking status: active: current = 53%, never n = 5; placebo: current = 33%, never n = 5
Diagnostic criteria (pneumonia): clinical and imaging findings in the presence of pneu-
mococcus in sputum
Etiological diagnosis (pneumococcus): diagnosis only if pathogens isolated from blood
or body fluids. Processed < 6 hours after collection
Microbiological methods described
Baseline characteristics (smoking status):
- Current smokers: PLA: 27/53; VAX: 17/50 (P = 0.036 for difference); non-smokers:
PLA: 5; VAX: 5
Interventions Vaccine type: 14 pneumococcal capsular polysaccharide antigens
Number in each group: intervention = 50; placebo = 53
Dose: 0.5 mL (50 mcg of each of the 14 capsular antigens)
Delivery: subcutaneous injection
Cointerventions: none
Comparison: saline
Duration of study: 24 to 32 months
Participants followed up for 48months (mean follow-up in each arm: PLA: 32.2months;
VAX: 31.7 months)
Outcomes Incidence of pneumonia: community-acquired pneumonia and putative pneumococcal
pneumonia: clinical and imaging findings in the presence of pneumococcus in sputum
Pneumonia-free survival plots: no hazard ratio, P = 0.249
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Davis 1987 (Continued)
All-cause mortality survival plots: no hazard ratio, P = 0.718
Antibody titers: not analysed
Sputum flora: not analysed
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study participants arranged in a double-
blind manner on the basis of a table of ran-
dom numbers to a group receiving placebo
or to a group receiving vaccine
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Assessors
Low risk Double-blind study; study outcomes as-
sessed by person blinded to Tx allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study; placebo injection
given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of withdrawals/losses to follow-up
similar in both groups
Selective reporting (reporting bias) Low risk Protocol not available but all outcomes
specified in methods are reported
Other bias Low risk None noted
Dransfield 2009
Methods Design: randomised controlled trial, parallel group
Setting: NHLBI COPD Clinical Research Network; 10 centres, USA
Comments: study registered online (NCT00457977) and completed in May 2011
Author’s name: Mark T. Dransfield
Institution: National Heart, Lung and Blood Institute
Email: mdransfield99@msn.com
Address: University of Alabama at Birmingham and the BirminghamVAMedical Center,
422 THT, 1900 University Blvd, Birmingham, AL 35294, USA
Follow-up: 48 months
Participants Inclusion criteria:
- > 40 yo male and female
- ≥ 10 pack-year cigarette smoking history
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Dransfield 2009 (Continued)
- Clinical diagnosis of moderate to very severe COPD (defined as FEV1/FVC < 70%
and FEV1 < 70% predicted)
- Never received PPSV-23 OR did not receive PPSV-23 during the 5 years before ran-
domisation
Exclusion criteria:
- Diagnosis of asthma
- Sensitivity to pneumococcal vaccination
- Bleeding disorder, chronic anticoagulation or the presence of conditions known to
impair pneumococcal vaccine response
- Acute illness requiring antibiotics or steroids within the past month or not expected to
survive 12 months
N = 181; PPSV-23 n = 90, PCV-7 n = 91
No statistically significant differences between pretreatment groups was reported
Age, years (%): 64 (10); 63 (9)
FEV1 (% predicted): 44.8 (15); 44.9 (15)
ICS use %: 64; 66
Current smoker %: 36; 36
Pack-years of smoking: 55 (27); 52 (28)
Male %: 37; 38
LTOT %: 32; 23
Previous pneumonia %: 45; 44
Hospitalisation or unscheduled emergency visit (≤ 1 year before enrolment) %: 11; 18
Received systemic steroids and/or antibiotics %: 34; 38
Vaccine naive %: 42; 45
Years since last vaccination %: 8.4 ± 3.5; 7.6 ± 2.7
Interventions 23-Valent pneumococcal polysaccharide vaccine (PPV-23) 0.5 mL intramuscular
7-Valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV-7) 1.0 mL
intramuscular
Outcomes Vaccine responsiveness: antibody levels (IgG) not included in meta-analysis
Acute exacerbation COPD
- Pneumonia: self-reported by participants; no diagnostic criteria described
- Hospitalisation
- Fatigue
- Headache
- Limitation of arm movement
- Redness or discolouration ≤ 15 cm
- Redness or discolouration > 15 cm
- Localised swelling
Notes Sponsorship source: 639191; National Heart, Lung and Blood Institute of the Na-
tional Institutes of Health (U10 HL074441, U10 HL074418, U10 HL074428,
U10HL074409, U10 HL074407, U10 HL074422, U10 HL074416, U10 HL074408,
U10 HL074439, U10 HL074431, U10 HL074424)
Risk of bias
Bias Authors’ judgement Support for judgement
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Dransfield 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was performed after link-
ing to the clinical trial co-ordinating centre
website and stratified by study centre
Allocation concealment (selection bias) Low risk Independent third party allocation. Ran-
domisation was performed after linking to
the clinical trial co-ordinating centre web-
site and stratified by study centre
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Open-label trial with no blinding
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were not blinded, PPV group
received influenza, control group received
only influenza. Lack of blinding was not
likely to affect measurement of dichoto-
mous outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Approximately 15% of people in both
groups were lost to follow up and exited the
study early. Reasons for withdrawal were
given
Selective reporting (reporting bias) Low risk All outcomes reported in methods and trial
registration are available in publications
Other bias Unclear risk Trial relied in part on self-reported vacci-
nation; some participants may have been
misclassified as vaccine naive or previously
vaccinated, or may have been enrolled < 5
years after previous PPSV-23
Furumoto 2008
Methods Study design: parallel-group randomised controlled trial
Location, number of centres: 13 hospitals in the district of Kyushu and Okinawa, Japan
Duration of study: 2 years (November 2001 to April 2002)
Participants Number screened:≥ 383 potentially eligible patients with CLD contacted by researchers
Number randomised: 191 (55 with COPD)
Number completed: 167; intervention group n = 87, control group n = 80
Gender distribution: intervention = 69% male; control = 57.5% male
Mean age (years): intervention = 67.8 (SD 9); control 70.1 (SD 9.5)
Inclusion criteria:
- Patients with chronic lung disease (CLD) who previously experienced acute exacerba-
tions and were able to comply with a schedule of monthly clinical visits
- Between 40 and 80 years of age
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Furumoto 2008 (Continued)
- Investigators selected participants. No diagnostic criteria for COPD were given
Exclusion criteria:
- Patients who were pregnant or were immunocompromised, with conditions such as
active malignant disease, renal insufficiency in dialysis or HIV infection, hypogamma-
globulinaemia or anatomical or functional asplenia, who had previously received 23-
valent PV (Pneumovax, Banyu, Japan)
Baseline details: Participants with CLD included 55 with COPD (24 PV + IV, 31 IV), 50
with sequelae of pulmonary TB (33 PV + IV, 17 IV), 62 with other CLD (bronchiectasis
20, asthma 13, pneumoconiosis 14, interstitial pneumonia 9, diffuse panbronchiolitis
5, sarcoid 1) (30 PV + IV, 32 IV)
Interventions Vaccine type: intervention pneumococcal polysaccharide vaccine (PV) and a triva-
lent, split virion, influenza vaccine (IV) containing A/NewCaledonia/20/99H1N1, A/
Panama/2007/99H3N2 and B/Johannesburg/5/99 for the 2001/2002 season; for the
2002/2003 season, a vaccine containing A/NewCaledonia/20/99H1N1, A/Panama/
2007/99H3N2 and B/Guangdong/7/97
Control: a trivalent, split virion, influenza vaccine containing A/NewCaledonia/20/
99H1N1, A/Panama/2007/99H3N2 and B/Johannesburg/5/99 for the 2001/2002 sea-
son; for the 2002/2003 season, a vaccine containing A/NewCaledonia/20/99H1N1, A/
Panama/2007/99H3N2 and B/Guangdong/7/97 but no PV
Outcomes Primary outcomes:
- Time to first episode of pneumonia or to acute exacerbation (AE) after enrolment in
the study: data not available for participants with COPD only
- Pneumonia: diagnostic criteria: clinical symptoms (cough, sputum or fever) plus in-
creased WBC count or increased C-reactive protein or appearance of new infiltration on
CXR; data available for participants with COPD
- Exacerbations: definition: 2 or 3 of increased dyspnoea, increased sputum volume,
increased sputum purulence plus absence of new infiltration on CXR, or 1 of these
symptoms and 1 additional symptom plus absence of new infiltration on CXR; data
available for participants with COPD. Kaplan-Meier survival curves for infectious acute
exacerbation demonstrated a significant difference between the 2 groups (P = 0.041)
- Infectious acute exacerbation: defined by increase in WBC count or increased C-
reactive protein. Pneumoccal AE: defined as isolating sputum S pneumoniae. Participants
examined monthly by study investigators. Asked to visit study hospital at any onset fever,
cough or sputum, or if experiencing breathlessness during 2-year period; data available
for participants with COPD
Secondary outcomes:
- Mortality data not available for participants with COPD alone
Notes Data included only for participants with COPD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomly assigned in
equal proportions to either group
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Furumoto 2008 (Continued)
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed en-
velopes were held by study administrators
Blinding (performance bias and detection
bias)
Assessors
High risk No attempt was made to blind clinical as-
sessors to vaccine allocation in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were not blinded; PPV group
received influenza, and control group only
received influenza. Lack of blindingwas not
likely to affect measurement of dichoto-
mous outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk During 2-year follow-up period, 2 and 11
participants were lost from the PV + IV
and IV groups, respectively. In addition,
early termination of follow-up occurred for
5 participants from the PV + IV group and
for 6 participants from the IV group be-
cause they wanted to withdraw from the
study. Subsequently, 87 participants in the
PV + IV group and 80 in the IV group
completed the analysis
Selective reporting (reporting bias) Low risk The study protocol was not available, but
it appears that published reports included
prespecified outcomes
Other bias Low risk None noted
Kostinov 2014
Methods Sponsorship source: not stated
Country: Russia
Setting: 2 centres:MechnikovResearch Institute of Vaccines and Sera,Ministry ofHealth
Omsk; Polyclinic Tyumen
Authors’ names: Kostinov MP, Ryzhov AA, Magarshak OO, Zhirova SN, Protasov AD,
Erofeev YUV, Miunova OV, TOlokonnikova IN, Liverko EV
Institution: Mechnikov Research Institute of Vaccines and Sera, Moscow
Participants Design: randomised controlled trial, parallel group
Follow-up: 12 months
Inclusion criteria:
- Participants 30 to 55 years of age
- Diagnosis of COPD according to GOLD 2011 - on the basis of patient history,
complaints: cough, sputum production, shortness of breath worsening on exercising
- All patients had undergone spirometry and bronchodilator reversibility testing (400
mcg of salbutamol).
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Kostinov 2014 (Continued)
- FEV1 reversibility < 12% (or < 200 mL), ratio FEV1/FVC < 70%
Exclusion criteria:
- Age < 30, > 50
- Pneumococcal vaccination over past 3 years
- Acute infection (TB, active phase of chronic viral hepatitis), mental disorders, renal
or hepatic insufficiency, neoplastic disease, chronic disease in exacerbations, hypersen-
sitivity to vaccine components, severe complications of prior vaccinations, pregnancy,
autoimmune disease
Groups: PPSV-23 n = 100; no vaccine n = 100
Age (years): 30 to 50
FEV1 % predicted: not known
ICS use %: not known
Current smoker %: not known
Pack-years of smoking: not known
Male: 41 (41%); 31 (31%)
LTOT: not known
Previous pneumonia: not known
Hospitalisation or unscheduled emergency visit (≤ 1 year before enrolment): 16; 6
Interventions Vaccine Pneumo-23 (Sanofi, France), intramuscular 0.5 mL, once after signing of in-
formed consent
Outcomes Acute exacerbation COPD
Hospitalisation
Notes Publication in Russian. Liliya Eugenevna Ziganshina
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patientswere randomised into groupswith
the use of the method of serial (sequential)
numbers” in translated text
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Assessors
Unclear risk No information provided, no reference to
blinding
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No reference to blinding but no placebo
given in control group
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of participants randomised to
treatment and number of participants anal-
ysed the same; no withdrawals reported
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Selective reporting (reporting bias) Low risk Results for all outcome measures were re-
ported.
Other bias Low risk No issues of concern in translation of paper
Leech 1987
Methods Setting: Montreal Chest Hospital (stable ambulatory population)
Study design: randomised, double-blind, placebo-controlled trial
Type of analysis: case available
Follow-up: 24 months
Participants Total number of participants: 189
Gender distribution (male): vaccine = 66; placebo = 69
Mean age of participants (years): vaccine = 66 ± 9; placebo = 67 ± 9
Age range (years): 40 to 89
Inclusion criterion for active group: patients seen in outpatient clinic who had COPD
(FEV1 < 1.5 L)
Exclusion criteria: previous pneumococcal vaccination, asthma, cystic fibrosis or
bronchiectasis
Diagnostic criteria (COPD): not stated, other thanprior diagnosis ofCOPDbyphysician
Severity of COPD: vaccine group (mean) FEV1 = 0.94 L; FVC = 2.18 L/s; placebo group
(mean) FEV1 = 0.96 L; FVC = 2.13 L/s
Microbiological diagnosis (pneumococcus): not stated, although sputum cultured in
10% of participants
N = 189 (VAX: 92; PLA: 97)
Gender distribution: PLA = 69 M; VAX = 66 M
Mean age: PLA = 67 (SD 9); VAX = 66 (SD 9); FEV1 (L): PLA = 0.96 (SD 0.30); VAX
= 0.94 (SD 0.26); FVC: PLA = 2.13 (SD 0.64); VAX = 2.18 (SD 0.58)
Interventions Vaccine types: 14-valent pneumococcal polysaccharide (in 1 arm) and influenza vacci-
nation (in the other arm)
Numbers in each group: intervention = 92; placebo = 97
Dose: not stated
Delivery: injection
Cointerventions: none
Comparison: saline (in 1 arm) and influenza vaccination (in the other arm)
Follow-up points: 6-month intervals
Duration of study: 2 years
Influenza vaccination (given at baseline, end of years 1 and 2, unless previous adverse
reaction or declined)
Outcomes Incidence of pneumonia: diagnostic criteria (pneumococcal pneumonia): pneumonia
defined as symptoms of lower respiratory tract infection (fever, increased cough and
change in colour or increase in quantity of sputum) and evidence of new infiltrate on
chest x-ray
Upper respiratory tract infection (URTI): definition: symptoms of sore throat, runny
nose, fever and increased cough without increase in quantity or change in colour of
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Leech 1987 (Continued)
sputum
Mortality (all-cause)
Hospital admission (all-cause); length of hospital stay; emergency visits (all causes);
hospital admissions, emergency visits to clinic or emergency department assessed by
participant/family interview and chart review
Adverse events (pneumococcal sepsis)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Makes reference to study participants “ran-
domly assigned” to control or intervention
group; however, does not make reference
to method of sequence generation Partici-
pants stratified by age and FEV1
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Described as double-blind study but no in-
formation on blinding of assessors given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study with placebo injection
given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 23 patients (12%) could not
be traced for follow-up and were not in-
cluded in the analysis of death rates. At each
follow-up interview some patients refused
to answer questions and were not included
in the analysis of hospital admissions and
emergency visits. 59% followed up at 24
months”
Selective reporting (reporting bias) Low risk The study protocol was not available, but
it appears that published reports include
prespecified outcomes
Other bias Low risk No other issues identified
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Lin 2013
Methods Sponsorship source: not declared in trial registration
Country: Taiwan (from March 2009 to May 2010)
Setting: outpatient department of tertiary medical centre, Chest Division, Department
of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
Authors’ names: Ming-Tzer Lin1,2,3 , Shih-Lung Cheng4
Institution: Far Eastern Memorial Hospital, Taipei City, Taiwan
Email: lightpool2010@gmail.com
Addresses: Department of Internal Medicine, Hsiao Chung-Cheng Hospital; Depart-
ment of Internal Medicine, National Taiwan University Hospital; Graduate Institute
of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan
University
Design: randomised controlled trial, parallel group
Participants Inclusion criterion:
- Diagnosis COPD (FEV1/FVC < 70% with exposure to smoking) with high daily dose
of ICS (beclometasone equivalent dose > 1000 mcg/d)
Exclusion criterion:
- Received PPSV-23 in recent 5 years or immunosuppressed status
Group differences: Demographic data were compatible between groups, except PPSV-
23 group had higher number of previous pneumonia episodes than control group (P =
0.038)
PPSV-23 n = 19, placebo n = 17
Age (years): 68.9 (9.2); 72.8 (6.7)
FEV1 % predicted: 43.1 (12.3); 46.5 (11.1)
ICS use %: 100% 2000 mcg BDP (1250 to 2000); 100% 1500 mcg BDP (1250 to
2000)
Current smoker %: 10 (52%) ; 4 (24%)
Pack-years smoking: 57.8 (32.1); 62.7 (32.8)
Male: 18 (95%); 14 (82%)
Long-term oxygen therapy: 3 (16%); 3 (18%)
Previous pneumonia in past 1 year: 0; 0
Hospitalisation or unscheduled emergency visit (≤ 1 year before enrolment): 1 (0 to 3)
; 1 (0 to 2)
Received systemic steroids and/or antibiotics: NA; NA
Vaccine naïve: NA; NA
Years since last vaccination: > 5: > 5
Interventions PPSV-2323-Valent pneumococcal polysaccharide vaccine 0.5 mL subcutaneously
Placebo normal saline 0.5 mL subcutaneously
Outcomes Acute exacerbation COPD (person-years). Moderate exacerbation defined as an exacer-
bation treated with parenteral corticosteroids with or without an antibiotic
Pneumonia in person-years. Pneumonia was diagnosed according to primary clinician’s
judgement
Hospitalisation in person-years
Death
Change in lung function (postbronchodilator FEV1, FVC) listed in trial registration but
not reported in conference presentation
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Notes Data supplied as conference presentation
ClinicalTrials.gov Identifier: sponsor: NCT01381367
Far Eastern Memorial Hospital: first received: 16 February 2009
Information provided by Far Eastern Memorial Hospital
Last updated: June 24, 2011; last verified: June 2011
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as double-blinded, randomised
controlled trial. Method of randomisation
not reported
Allocation concealment (selection bias) Unclear risk Described as double-blinded, randomised
controlled trial. Allocation after enrolment,
method not reported
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Described as double-blinded. Placebo used
in control group. No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blinded. Placebo used
in control group. No details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 36 patients recruited: 19 PPSV-23/17
placebo. Outcome data for all participants
reported
Selective reporting (reporting bias) Low risk All primary and important secondary out-
comes listed in trial registration were avail-
able in poster report. Lung function not re-
ported
Other bias Low risk Study not fully published, but poster pre-
sentation includes study methods and re-
sults. No other issues noted
Steentoft 2006
Methods Setting of study: hospital-based
Study design: RCT parallel: 1 control group with 3 levels of steroid load, block-ran-
domised to vaccine or to no vaccine
Type of analysis: case available
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Participants Total number of participants: 49
Gender distribution: M = 27; F = 22
Mean age: control: 67.5 years
Intervention: 65, 72 and 71 years for the 3 groups
Age range (years): 47 to 86
Inclusion criterion: COPD
Diagnostic criteria (COPD): COPD defined by GOLD guidelines (FEV1/FVC < 70%,
FEV1 reversibility-test < 200 mL)
Exclusion criterion: prior pneumococcal vaccine
Severity of COPD at baseline:
- Control: FEV1% = 50.2
- Intervention: FEV1% = 48.2, 46.0 and 44.2 for the 3 groups
Smoking status:
- Active: current = 46%, past = 54%
- Placebo: current = 58%, past = 42%
Diagnostic criterion (pneumonia): radiologically verified, but no other criteria stated
Etiological diagnosis (pneumococcus): not described
Interventions Vaccine type: 23-polyvalent pneumococcal vaccine
Numbers in each group:
- Intervention = 37
- Placebo = 12
Dose: 0.5 mL
Delivery: subcutaneous injection
Cointerventions:
- Three groups with various exposure patterns to oral prednisolone
* No steroids 3 months before vaccination, then steroids for 4 weeks after vaccination
* Long-term steroid treatment, before and after vaccination
* Vaccination after 4 weeks with steroid treatment, then no steroids after vaccination
Groups 1 and 3 above received 37.5 mg starting dose of prednisolone, tapered to 0
during respective time frames
Comparison: no vaccine
Duration of study: 6 months
Outcomes Types of outcomes measured:
- Acute exacerbations (definition: incidents with fever and expectoration)
- Pneumonia (definition: radiologically verified pneumonia)
- Number of hospital admissions (all-cause)
- Improvement/worsening in lung function (reported, not analysed)
- Extra prednisone use: not analysed
- Extra beta agonist use: not analysed
- Antibiotics: not analysed
- Antibody titres post vaccination- not analysed
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were block-randomised to vac-
cine or no vaccine.
Allocation concealment (selection bias) Low risk Third party held randomisation schedule.
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Not stated for clinical diagnoses if out-
comes assessed by person blinded to Tx
allocation. Laboratory staff assessing anti-
body levels were blinded to allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo injection given in control
group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data on withdrawals given
Selective reporting (reporting bias) Low risk The study protocol was not available, but
it appears that published reports include
prespecified outcomes
Other bias Low risk None noted
Teramoto 2007
Methods Study design: parallel-group randomised controlled trial
Setting: Toyko, Japan
Duration of study: 2 years
No funding declared
Participants Number screened: not available
Number randomised: 196
Number completed: unclear
Gender distribution: not reported
Mean age and range (years): 77.8 (75.1 to 80.5)
Inclusion criteria: elderly patients with COPD, diagnostic criteria not stated
Exclusion criteria: not reported
Interventions Intervention: 23-valent pneumococcal polysaccharide vaccine
Control: no vaccination
Cointerventions: none
Treatment period: single PPV vaccination administered to intervention group
Follow-up period: 2 years
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Teramoto 2007 (Continued)
Outcomes Pneumonia: definition: radiographically proven community-acquired pneumonia of
pneumococcal or unknown aetiology. Survival plot for community acquired pneumonia:
no significant difference reported
Notes Study available only as abstract publication. Study author contacted for details of study
and outcome data 25/09/09, but no response received by 01/03/10
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No mention of allocation sequence gener-
ation method, although study described as
randomised
Allocation concealment (selection bias) Unclear risk No description of method used
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Nomention regarding blinding of assessors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo injection given in control
group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on withdrawals after ran-
domisation
Selective reporting (reporting bias) Unclear risk One outcome reported in abstract. Other
data not published yet
Other bias Low risk None noted
Trofimov 2010
Methods Sponsorship source: not known
Country: Russia
Setting: St Petersburg State Medical University
Author’s name: Tromifov VI
Institution: ZH, Mikrobiol, Moscow
Design: randomised controlled trial, parallel group
Participants Inclusion criteria for types of participants recruited into the study were not reported
Exclusion criteria for types of participants recruited into the study were not reported
Group differences: groups comparable by age, sex, history and lung function
PPSV-23 n = 20: control n = 25
Male: 14/20 (70%); 16/25 (64%)
Age (years): 56.38 (2.78); 52.75 (2.48)
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Trofimov 2010 (Continued)
FEV1 % predicted: 55.8 (2.8); 67.7 (3.1)
ICS use %: not known
Current smoker %: not known
LTOT: not known
Previous pneumonia: not known
Hospitalisation or unscheduled emergency visit (≤ 1 year before enrolment): not known
Received systemic steroids and/or antibiotics: not known
Vaccine naive: not known
Years since last vaccination: not known
Pack-years of smoking: not known
Interventions PPSV-23: Vaccine Pneumo-23 Injectable, route of delivery not reported, dosage not
reported
Control: standard treatment
Outcomes Stable remission of disease during follow-up of 6 months
Notes Paper in Russian. Translator: Liliya Eugenevna Ziganshina 24/03/15
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described in translated text as open ran-
domised study, but no method specified
Allocation concealment (selection bias) Unclear risk No information on allocation
Blinding (performance bias and detection
bias)
Assessors
High risk Open randomised study; no placebo
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open randomised study; placebo not given
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 45 participants randomised; no informa-
tion on withdrawals
Selective reporting (reporting bias) Unclear risk Lung function, blood count, sputum cytol-
ogy, immunological parameters and stabil-
ity of disease were listed as outcomes. Re-
sults for lung function were not presented.
All intervention groups were described as
having ’stable remissionof disease’ and20%
in standard treatment group
Other bias Low risk None noted
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Ya Tseimakh 2006
Methods Setting of study: Barnaul, Russia
Study design: parallel-group randomised controlled trial
Duration of study: 6 months
Participants Number screened: not available
Number randomised: 373
Number completed: 373
Gender distribution: not available
Mean age (years): intervention 57.9 ± 0.51; control 57.8 ± 0.95
Inclusion criteria:
- Patients with COPD (diagnostic criteria not stated)
- Age 18 to 70 years
- Frequency of exacerbations of COPD before beginning of studies ≥ 2 times per year
Exclusion criterion:
- Patients with immunodeficiency, long-term systemic glucocorticoids
Interventions Intervention: pneumococcal polysaccharide vaccine ’Pneumo 23’
Control: no vaccine.
Cointerventions: none
Treatment period: single vaccination given to control group
Follow-up period: 6 months
Outcomes COPD exacerbations - no definition given: reported mean rate with SD
Acute respiratory infection (ARI): no definition given
Adverse events (erythema, induration, fever, headache): % reported for vaccine group
Notes Only interim results available, as abstract publication. Study authors contacted for 12-
month data without response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised controlled trial; no descrip-
tion of method used for randomisation
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
method used; control group did not receive
treatment
Blinding (performance bias and detection
bias)
Assessors
High risk No blinding of participants or study per-
sonnel
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo injection given in control
group
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Ya Tseimakh 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information supplied regarding with-
drawals
Selective reporting (reporting bias) Unclear risk Publication as abstract only; no response to
request data
Other bias Low risk No other issues identified
Yilmaz 2013
Methods Sponsorship source: no information available
Country: Turkey/UK
Setting: tertiary hospital, conducted between July 2006 and October 2008
Comments: “Publication details abstract 2013; 187 (meeting abstracts): A2182. Unpub-
lished data requested and supplied by author”
Authors’ names: Yilmaz D, Uzaslan E, Ege E
Institution: Uludad University Medical Faculty, Bursa/St George’s, London
Email, Dilber Y lmaz Durmaz: drdilberyilmaz@gmail.com
Address: StGeorge’sHospital, University of London, UludagUniversityMedical Faculty,
Bursa, Turkey
Design: randomised controlled trial, parallel group
Follow-up: 24 months
Participants Inclusion criteria:
- Clinical diagnosis of COPD ≥ 12 months before baseline visit
- Age ≥ 40
- Written informed consent
- Former or current smoker with a smoking history ≥ 10 pack-years
Exclusion criteria:
- Vaccination with PPV within previous 5 years
- Immune suppression
- Chronic renal failure
- Bronchiectasis
- Previous lung surgery
- Malignancy
- COPD exacerbation or pneumonia within previous 30 days
- Unstable cardiac disease
- Pregnancy or suspected pregnancy
Group differences: PV and placebo group had no significant difference in terms of
age, sex, GOLD stages, annual influenza vaccination, pneumonia history, number of
exacerbations and pneumonia in the past 1 and 2 years (P > 0.05)
PPSV-23 n = 116; placebo n = 28
Group differences: no significant differences in baseline characteristics between the 2
groups. All differences between baseline characteristics were non-significant
Age (years): 65.3 ± 9.3; 64.9 ± 8.8
FEV1 (L): 1.48 (± 0.617); 1.408 (± 0.54)
ICS use %: NA; NA
Current smoker %: NA; NA
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Yilmaz 2013 (Continued)
Pack-years of smoking: 48.6 ± 27.9; 40.6 ± 23.6
Male: 108/116 (93%); 26/28 (93%)
LTOT: NA; NA
Previous pneumonia: 74 (63%); 16 (57%)
Hospitalisation or unscheduled emergency visit (≤ 1 year before enrolment): NA; NA
Received systemic steroids and/or antibiotics: NA; NA
Vaccine naive: 0; 0
Years since last vaccination: NA
Mean FEV1 (mL): 1438 ± 617; 1408 ± 540
Interventions PPSV-23: 23-valent PPV (Pneumo 23, Lyon, France), dose NA, route not stated
Placebo: not described
Outcomes Acute exacerbation COPD (defined as an acute event characterised by worsening of
respiratory symptoms beyond normal day-to-day variations)
Courses of antibiotics
Hospitalisation
Death
Emergency department visits
FEV1 (L)
SGRQ (St George’s Respiratory Questionnaire)
Notes Published as abstract; full unpublished manuscript supplied by study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, prospective, sin-
gle-blind, 24-month trial; no details on
randomisation schedule
Allocation concealment (selection bias) Unclear risk Randomised, prospective, single-blind, 24-
month trial; no details on allocation
method. Unequal group numbers 3:1 (ac-
tive:placebo)
Blinding (performance bias and detection
bias)
Assessors
Unclear risk Described as prospective, single-blind, 24-
month trial; no details on which group was
blinded
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Described as prospective, single-blind trial.
No indication that placebo injection was
used in control group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Study authors report that all participants
were followed to the end of 2 years
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Yilmaz 2013 (Continued)
Selective reporting (reporting bias) Low risk All results were reported. Results for all out-
comes listed in methods were reported
Other bias Low risk No other issues identified
AE: acute exacerbation; ARI; acute respiratory infection; ATS: American Thoracic Society; C; control; CLD: chronic lung disease;
COPD: chronic obstructive pulmonary disease; CSF: cerebrospinal fluid; CXR: chest x-ray; F: female; FEV1: forced expiratory
volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; HIV: human
immunodeficiency virus; I: intervention; ICS: inhaled corticosteroids; IgG: immunoglobulin G; IV: influenza vaccine; LTOT: long-
term oxygen therapy; M: male; MSD: Merck Sharpe and Dohme; NHLBI: National Heart, Lung and Blood Institute; PCV:
pneumococcal conjugated vaccine; PLA: placebo; PPSV: pneumococcal polysaccharide vaccine; PV: polysaccharide vaccine; RCT:
randomised controlled trial; S pneumoniae: Streptococcus pneumoniae; SD: standard deviation; TB: tuberculosis; Tx: treatment; VA:
Veterans Administration; VAX: vaccination; WBC: white blood cell
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aboussouan 1996 Review article
Austrian 1976 Participants are unlikely to have had COPD, and certainly no results are available for persons with COPD
Austrian 1981 Review article
Austrian 1984 Editorial
Bacle 1997 Review article
Bentley 1981 Review article
Bolan 1986 Not an RCT
Broome 1981 Review article
Butler 1992 Retrospective analysis of vaccine efficacy
Butler 1993 Retrospective analysis of vaccine efficacy
Chang 2012 Cohort study
Chodosh 1991 Review article
Christenson 2001 Prospective study (not an RCT)
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Dilokthornsakul 2014 Study observed the association between pneumococcal vaccine and thrombocytopaenia in participants with
COPD. Not an efficacy study of pneumococcal vaccinations in participants with COPD
Douglas 1979 Review article
Douglas 1984 Study carried out in children 6 to 54 months
Ekwurzel 1938 Excluded, as participants unlikely to have had COPD (“youthful group, 80% being under 25 years of age”)
Ewig 1999 Review article
Farr 1995 Matched case-controlled study
Fedson 1989 Review article
Fedson 1994 Review article
Fedson 1999 Review article
Felton 1938 Cohort observation study
Ferguson 1993 Review article
Filice 1990 Review article
Fine 1994 Meta-analysis
Forrester 1987 Case-controlled study
Foschino 1995 Oral immunomodulator (not injectable vaccine)
Gable 1990 Retrospective cohort study
Gaillat 1985 No data available for participants with COPD
Gaillat 2009 Narrative review
Gardner 1993 Review article
Greenberg 2014 Wrong patient population. Participants were not patients with COPD
Gross 2010 Narrative review
Hak 1998 Prospective cohort study
Halasa 2001 Injectable vaccine includes antigen from pneumococcus and other bacteria (written in Polish language)
Han 2011 Narrative review
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Hilleman 1981 Review article
Hirschmann 1981 Review article
Hirschmann 1994 Commentary
Horwood 2002 Review article
Hughes 2011 Cross-sectional study of predictors of colonisation of Pneumococcus bacterium in participants with COPD
Hung 2010 Prospective cohort study
Jackson 2003 Retrospective cohort study
Jimenez-Garcia 2007 Descriptive study of influenza and pneumococcal vaccination coverage among participants suffering from
COPD
Jonsson 2002 Study compares 23 valent pneumococcal vaccine or type 6B polysaccharide conjugated to tetanus toxoid in
participants with COPD vs healthy adult controls
Kaiser 1974 Retrospective analysis of isolates
Kaufman 1941 Participants not adequately randomised. Participants allocated to active treatment by volunteering 1 year
followed by by alternate allocation in the subsequent year
Kaufman 1947 Likely to have included participants with COPD, given the age range of those involved in the study (80%
> 60 years), although inclusion of persons with COPD was not explicitly stated. Request was made to
originating institutions to provide relevant analyses of COPD subgroup, but no response was obtained
Klastersky 1986 No data available for participants with COPD
Klein 1983 Trial of immunisation rates
Koivula 1997 No data available for participants with COPD
Kraus 1985 Study of antibody responses
LaForce 1989 Review article
Lai 2007 Experimental study of antibody responses to a 23-valent pneumococcal polysaccharide vaccine and clinical
outcome in Taiwanese participants with COPD
Landesman 1983 Study of antibody responses
Larsson 1998 Review article
Lee 2007 Retrospective cohort study
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Leophonte 2001 Review article
MacIntyre 2010 Study assessed safety of concomitant zoster vaccination with pneumococcal vaccination in healthy partici-
pants without COPD
MacLeod 1945 CCT in young adults; COPD unlikely
Madison 1998 Review article
Meyer 2006 Comparison of Pneumovax given by inhalation, alveolar vaccination or bronchial vaccination vs standard
intramuscular vaccination. No placebo control
Monso 2003 Commentary
Nichol 1999 Retrospective cohort control study
Ochoa-Gondar 2008 Prospective cohort study
Orcel 1994 Oral immunomodulator (not injectable vaccine)
Ortqvist 1998 No data available for participants with COPD
Patrick 1981 Cost/benefit analysis
Preheim 1978 Case report
Ricci 2014 Wong intervention. Study assessed efficacy of a sublingual pneumococcal vaccination
Riley 1977 No data available for participants with COPD
Rochemaure 1988 Antigens for this oral immunomodulator are taken from Klebsiella pneumoniae and Escherichia coli (not
Streptococcus pneumoniae).
Saag 1998 Survey
Schenkein 2008 Narrative review of pneumococcal vaccination in COPD. Not an RCT
Schnelle 2010 Not an RCT
Schwartz 1982 Review article
Sehatzadeh 2012 Meta-analysis
Shapiro 1984 Case-controlled study
Shapiro 1987 Correspondence
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Shapiro 1991 Case-controlled study
Sheikh 1999 Asthma study
Simberkoff 1986 No data available for participants with COPD
Simberkoff 1993 Review article
Sims 1988 Case-controlled study
Sisk 1986 Cost/benefit analysis; no data on efficacy
Smit 1977 Participants were young adult novice miners, with no indication of chronic lung disease. Wrote to study
authors for further information, but received no response (Oct 2004)
Sumitani 2008 Not an RCT. Observational study; participants immunised with influenza vaccine (I-V) and 23-valent
pneumococcal vaccine (P-V)
Van Amptin 1998 Retrospective study of patients hospitalised with infection
Vila-Corcoles 2012 Case-controlled study
Watanuki 2007 Cohort follow-up study. Study author request for study details 12/05/09, but no response received
Wencker 1999 Alpha 1 antitrypsin deficiency
Wenzel 1976 Inappropriate intervention including mycoplasma rather than Streptococcus pneumoniae
WHO 1999 Position paper
WHO 1999b Review article
Wiebel 1977 Antibody response study
Willems 1980 Non-randomised cost-effectiveness study
Williams 1986 Review article
Wright 1914 Participants were young (otherwise healthy) mining labourers with no indication of having COPD
CCT: case-controlled trial; COPD: Chronic obstructive pulmonary disease; RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Pneumococcal vaccine versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Community-acquired
pneumonia: at least 1 episode
6 1372 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.43, 0.89]
1.1 PPV-23 serotypes 5 1269 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.42, 0.89]
1.2 PPV-14 serotypes 1 103 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.17, 3.68]
2 Community-acquired
pneumonia: rate per
person-year
1 Rate Ratio (Fixed, 95% CI) Subtotals only
2.1 PPV-23 serotypes 1 36 Rate Ratio (Fixed, 95% CI) 0.37 [0.12, 1.14]
3 Pneumococcal pneumonia: at
least 1 episode
3 1158 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.26 [0.05, 1.31]
3.1 PPV-23 serotypes 2 969 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.13 [0.02, 0.78]
3.2 PPV-14 serotypes 1 189 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.80 [0.15, 393.72]
4 Death from cardiorespiratory
causes
3 888 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.69, 1.66]
4.1 PPV-23 serotypes 1 596 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.66, 1.88]
4.2 PPV-14 serotypes 2 292 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.44, 2.18]
5 Death from all causes 5 1053 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.40]
5.1 PPV-23 serotypes 3 761 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.69, 1.51]
5.2 PPV-14 serotypes 2 292 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.48, 1.86]
6 Hospital admission, any cause:
at least 1 episode
3 391 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.32, 1.74]
6.1 PPV-23 serotypes 3 391 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.32, 1.74]
7 Hospital admission:
cardiorespiratory-related
1 Rate Ratio (Random, 95% CI) Totals not selected
7.1 PPV-14 serotypes 1 Rate Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
8 Hospital admission: all-cause 1 Rate Ratio (Random, 95% CI) Totals not selected
8.1 PPV-23 serotypes 1 Rate Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
9 ED visit, any cause: at least 1
episode
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10 At least 1 COPD exacerbation 4 446 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.39, 0.93]
10.1 PPV-23 serotypes 4 446 Odds Ratio (M-H, Fixed, 95% CI) 0.60 [0.39, 0.93]
11 COPD exacerbation rate 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 PPV-23 serotypes 1 373 Mean Difference (IV, Fixed, 95% CI) -0.59 [-0.80, -0.38]
12 COPD exacerbations:
rate/person-year
1 Rate Ratio (Fixed, 95% CI) Subtotals only
12.1 PPV-23 serotypes 1 36 Rate Ratio (Fixed, 95% CI) 0.87 [0.44, 1.72]
13 Lung function: FEV1 (L) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 24 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Quality of life: SGRQ overall 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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14.3 24 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Comparison PPV-23 versus PCV-7
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Community-acquired
pneumonia: at least 1 episode
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Death from all causes 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Hospital admission, any cause:
at least 1 episode
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Acute exacerbation COPD 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Adverse effects 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Fatigue 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Headache 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Fever 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Pain 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Redness or discolouration
≤ 15 cm
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Redness or discolouration
> 15 cm
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.7 Localised swelling 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.8 Limitation of arm
movement
1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Analysis by follow-up period/subgroup
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pneumonia by lung function at
baseline
1 596 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.41, 1.22]
1.1 FEV1 < 40% expected 1 246 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.23, 1.00]
1.2 FEV1 ≥ 40% expected 1 350 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.50, 2.48]
2 Hospital admission, any cause:
by follow-up periods
3 377 Odds Ratio (M-H, Fixed, 95% CI) 0.54 [0.23, 1.22]
2.1 6-12 months 2 249 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.12]
2.2 12-24 months 1 128 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.11, 1.19]
3 Hospital admission,
cardiorespiratory-related: by
follow-up periods
1 Rate Ratio (Random, 95% CI) Subtotals only
3.1 7-12 months 1 160 Rate Ratio (Random, 95% CI) 0.89 [0.59, 1.36]
3.2 13-18 months 1 150 Rate Ratio (Random, 95% CI) 1.22 [0.69, 2.16]
3.3 19-24 months 1 112 Rate Ratio (Random, 95% CI) 0.70 [0.24, 1.99]
4 Emergency department visit, any
cause: by follow-up period
1 Odds Ratio (IV, Fixed, 95% CI) Totals not selected
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4.1 3-12 months 1 Odds Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 12-24 months 1 Odds Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Emergency visits (by cause) 1 Rate Ratio (Fixed, 95% CI) Subtotals only
5.1 Due to URTI 1 Rate Ratio (Fixed, 95% CI) 1.29 [0.68, 2.47]
5.2 Due to LRTI 1 Rate Ratio (Fixed, 95% CI) 1.00 [0.75, 1.33]
5.3 Due to pneumonia 1 Rate Ratio (Fixed, 95% CI) 0.99 [0.52, 1.88]
6 At least 1 COPD exacerbation:
varying follow-up
4 432 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.34, 0.81]
6.1 12 months 2 249 Odds Ratio (M-H, Fixed, 95% CI) 0.70 [0.41, 1.19]
6.2 > 12-24 months 2 183 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.15, 0.63]
Analysis 1.1. Comparison 1 Pneumococcal vaccine versus control, Outcome 1 Community-acquired
pneumonia: at least 1 episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 1 Community-acquired pneumonia: at least 1 episode
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PPV-23 serotypes
Alfageme 2006 (1) 25/298 33/298 41.4 % 0.74 [ 0.43, 1.27 ]
Furumoto 2008 (2) 6/24 5/31 4.5 % 1.73 [ 0.46, 6.56 ]
Steentoft 2006 (3) 11/37 5/12 7.3 % 0.59 [ 0.15, 2.28 ]
Teramoto 2007 (4) 16/100 32/96 37.5 % 0.38 [ 0.19, 0.75 ]
Ya Tseimakh 2006 (5) 2/297 2/76 4.3 % 0.25 [ 0.03, 1.81 ]
Subtotal (95% CI) 756 513 95.0 % 0.61 [ 0.42, 0.89 ]
Total events: 60 (Pneumococcal Vaccine), 77 (Control)
Heterogeneity: Chi2 = 5.42, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 2.57 (P = 0.010)
2 PPV-14 serotypes
Davis 1987 (6) 3/50 4/53 5.0 % 0.78 [ 0.17, 3.68 ]
Subtotal (95% CI) 50 53 5.0 % 0.78 [ 0.17, 3.68 ]
Total events: 3 (Pneumococcal Vaccine), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 806 566 100.0 % 0.62 [ 0.43, 0.89 ]
Total events: 63 (Pneumococcal Vaccine), 81 (Control)
Heterogeneity: Chi2 = 5.52, df = 5 (P = 0.36); I2 =9%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.05 0.2 1 5 20
Favours vaccine Favours control
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(1) 32 months median
(2) 24 months
(3) 6 months
(4) 24 months
(5) 6 months
(6) 24 months
Analysis 1.2. Comparison 1 Pneumococcal vaccine versus control, Outcome 2 Community-acquired
pneumonia: rate per person-year.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 2 Community-acquired pneumonia: rate per person-year
Study or subgroup Experimental Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 PPV-23 serotypes
Lin 2013 (1) 19 17 -0.9943 (0.5745) 100.0 % 0.37 [ 0.12, 1.14 ]
Subtotal (95% CI) 19 17 100.0 % 0.37 [ 0.12, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
0.01 0.1 1 10 100
Favours vaccine Favours control
(1) 12 months
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Analysis 1.3. Comparison 1 Pneumococcal vaccine versus control, Outcome 3 Pneumococcal pneumonia:
at least 1 episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 3 Pneumococcal pneumonia: at least 1 episode
Study or subgroup
Pneumococcal
Vaccine Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PPV-23 serotypes
Alfageme 2006 (1) 0/298 5/298 83.2 % 0.13 [ 0.02, 0.78 ]
Ya Tseimakh 2006 (2) 0/297 0/76 Not estimable
Subtotal (95% CI) 595 374 83.2 % 0.13 [ 0.02, 0.78 ]
Total events: 0 (Pneumococcal Vaccine), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
2 PPV-14 serotypes
Leech 1987 (3) 1/92 0/97 16.8 % 7.80 [ 0.15, 393.72 ]
Subtotal (95% CI) 92 97 16.8 % 7.80 [ 0.15, 393.72 ]
Total events: 1 (Pneumococcal Vaccine), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 687 471 100.0 % 0.26 [ 0.05, 1.31 ]
Total events: 1 (Pneumococcal Vaccine), 5 (Control)
Heterogeneity: Chi2 = 3.44, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 3.44, df = 1 (P = 0.06), I2 =71%
0.05 0.2 1 5 20
Favours vaccine Favours control
(1) 32 months median
(2) 6 months
(3) 24 months
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Analysis 1.4. Comparison 1 Pneumococcal vaccine versus control, Outcome 4 Death from
cardiorespiratory causes.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 4 Death from cardiorespiratory causes
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PPV-23 serotypes
Alfageme 2006 (1) 33/298 30/298 68.7 % 1.11 [ 0.66, 1.88 ]
Subtotal (95% CI) 298 298 68.7 % 1.11 [ 0.66, 1.88 ]
Total events: 33 (Pneumococcal Vaccine), 30 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 PPV-14 serotypes
Davis 1987 (2) 8/50 7/53 14.7 % 1.25 [ 0.42, 3.75 ]
Leech 1987 (3) 5/92 7/97 16.6 % 0.74 [ 0.23, 2.42 ]
Subtotal (95% CI) 142 150 31.3 % 0.98 [ 0.44, 2.18 ]
Total events: 13 (Pneumococcal Vaccine), 14 (Control)
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 440 448 100.0 % 1.07 [ 0.69, 1.66 ]
Total events: 46 (Pneumococcal Vaccine), 44 (Control)
Heterogeneity: Chi2 = 0.47, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 1.5. Comparison 1 Pneumococcal vaccine versus control, Outcome 5 Death from all causes.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 5 Death from all causes
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PPV-23 serotypes
Alfageme 2006 (1) 57/298 58/298 69.3 % 0.98 [ 0.65, 1.47 ]
Lin 2013 (2) 2/19 0/17 0.7 % 5.00 [ 0.22, 111.86 ]
Yilmaz 2013 (3) 9/104 2/25 4.4 % 1.09 [ 0.22, 5.39 ]
Subtotal (95% CI) 421 340 74.4 % 1.02 [ 0.69, 1.51 ]
Total events: 68 (Pneumococcal Vaccine), 60 (Control)
Heterogeneity: Chi2 = 1.05, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 PPV-14 serotypes
Davis 1987 (4) 10/50 11/53 12.6 % 0.95 [ 0.37, 2.49 ]
Leech 1987 (5) 9/92 10/97 13.0 % 0.94 [ 0.37, 2.44 ]
Subtotal (95% CI) 142 150 25.6 % 0.95 [ 0.48, 1.86 ]
Total events: 19 (Pneumococcal Vaccine), 21 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
Total (95% CI) 563 490 100.0 % 1.00 [ 0.72, 1.40 ]
Total events: 87 (Pneumococcal Vaccine), 81 (Control)
Heterogeneity: Chi2 = 1.08, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
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(1) 36 months
(2) 12 months
(3) 24 months
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Analysis 1.6. Comparison 1 Pneumococcal vaccine versus control, Outcome 6 Hospital admission, any
cause: at least 1 episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 6 Hospital admission, any cause: at least 1 episode
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PPV-23 serotypes
Kostinov 2014 (1) 1/100 3/100 24.7 % 0.33 [ 0.03, 3.19 ]
Steentoft 2006 (2) 18/37 6/12 38.7 % 0.95 [ 0.26, 3.48 ]
Yilmaz 2013 (3) 10/114 3/28 36.6 % 0.80 [ 0.21, 3.13 ]
Total (95% CI) 251 140 100.0 % 0.74 [ 0.32, 1.74 ]
Total events: 29 (Pneumococcal Vaccine), 12 (Control)
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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(2) 6 months
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Analysis 1.7. Comparison 1 Pneumococcal vaccine versus control, Outcome 7 Hospital admission:
cardiorespiratory-related.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 7 Hospital admission: cardiorespiratory-related
Study or subgroup Vaccine Control log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 PPV-14 serotypes
Leech 1987 (1) 76 84 -0.1112 (0.2887) 0.89 [ 0.51, 1.58 ]
0.02 0.1 1 10 50
Favours vaccine Favours control
(1) 7-12 months
Analysis 1.8. Comparison 1 Pneumococcal vaccine versus control, Outcome 8 Hospital admission: all-cause.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 8 Hospital admission: all-cause
Study or subgroup Vaccine Placebo log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 PPV-23 serotypes
Lin 2013 (1) 19 17 -0.1744 (0.5983) 0.84 [ 0.26, 2.71 ]
0.2 0.5 1 2 5
Favours vaccine Favours control
(1) 12 months
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Analysis 1.9. Comparison 1 Pneumococcal vaccine versus control, Outcome 9 ED visit, any cause: at least 1
episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 9 ED visit, any cause: at least 1 episode
Study or subgroup Experimental Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yilmaz 2013 (1) 6/114 5/28 0.26 [ 0.07, 0.91 ]
0.01 0.1 1 10 100
Favours vaccine Favours control
(1) 3-12 months
Analysis 1.10. Comparison 1 Pneumococcal vaccine versus control, Outcome 10 At least 1 COPD
exacerbation.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 10 At least 1 COPD exacerbation
Study or subgroup
Pneumococcal
Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 PPV-23 serotypes
Furumoto 2008 (1) 14/24 23/31 16.5 % 0.49 [ 0.16, 1.53 ]
Kostinov 2014 (2) 54/100 65/100 58.9 % 0.63 [ 0.36, 1.12 ]
Steentoft 2006 (3) 30/37 9/12 5.1 % 1.43 [ 0.31, 6.69 ]
Yilmaz 2013 (4) 13/114 7/28 19.6 % 0.39 [ 0.14, 1.08 ]
Total (95% CI) 275 171 100.0 % 0.60 [ 0.39, 0.93 ]
Total events: 111 (Pneumococcal Vaccine), 104 (Control)
Heterogeneity: Chi2 = 2.07, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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(1) 24 months
(2) 12 months
(3) 6 months
(4) 12 months
Analysis 1.11. Comparison 1 Pneumococcal vaccine versus control, Outcome 11 COPD exacerbation rate.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 11 COPD exacerbation rate
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 PPV-23 serotypes
Ya Tseimakh 2006 (1) 297 0.78 (0.8445) 76 1.37 (0.8282) 100.0 % -0.59 [ -0.80, -0.38 ]
Subtotal (95% CI) 297 76 100.0 % -0.59 [ -0.80, -0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.52 (P < 0.00001)
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Analysis 1.12. Comparison 1 Pneumococcal vaccine versus control, Outcome 12 COPD exacerbations:
rate/person-year.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 12 COPD exacerbations: rate/person-year
Study or subgroup Experimental Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 PPV-23 serotypes
Lin 2013 (1) 19 17 -0.1393 (0.3478) 100.0 % 0.87 [ 0.44, 1.72 ]
Subtotal (95% CI) 19 17 100.0 % 0.87 [ 0.44, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
0.5 0.7 1 1.5 2
Favours vaccine Favours control
(1) 12 months
Analysis 1.13. Comparison 1 Pneumococcal vaccine versus control, Outcome 13 Lung function: FEV1 (L).
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 13 Lung function: FEV1 (L)
Study or subgroup PSV 23 serotypes Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Yilmaz 2013 116 1.37 (18.6) 28 1.46 (19.2) -0.09 [ -7.97, 7.79 ]
2 12 months
Yilmaz 2013 114 1.43 (16.5) 28 1.55 (17.2) -0.12 [ -7.17, 6.93 ]
3 24 months
Yilmaz 2013 108 1.37 (18.5) 25 1.5 (22) -0.13 [ -9.43, 9.17 ]
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Analysis 1.14. Comparison 1 Pneumococcal vaccine versus control, Outcome 14 Quality of life: SGRQ
overall.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 1 Pneumococcal vaccine versus control
Outcome: 14 Quality of life: SGRQ overall
Study or subgroup PSV 23 serotypes Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Yilmaz 2013 116 31.23 (18.6) 28 34.99 (19.2) -3.76 [ -11.64, 4.12 ]
2 12 months
Yilmaz 2013 114 26.65 (16.5) 28 29.37 (17.2) -2.72 [ -9.77, 4.33 ]
3 24 months
Yilmaz 2013 108 28.3 (18.5) 25 36.19 (22) -7.89 [ -17.19, 1.41 ]
-20 -10 0 10 20
Favours vaccine Favours control
Analysis 2.1. Comparison 2 Comparison PPV-23 versus PCV-7, Outcome 1 Community-acquired
pneumonia: at least 1 episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 2 Comparison PPV-23 versus PCV-7
Outcome: 1 Community-acquired pneumonia: at least 1 episode
Study or subgroup PPV23 PCV7 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dransfield 2009 (1) 10/90 10/91 1.01 [ 0.40, 2.56 ]
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Analysis 2.2. Comparison 2 Comparison PPV-23 versus PCV-7, Outcome 2 Death from all causes.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 2 Comparison PPV-23 versus PCV-7
Outcome: 2 Death from all causes
Study or subgroup PPV23 PCV7 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dransfield 2009 (1) 7/90 4/91 1.83 [ 0.52, 6.50 ]
0.01 0.1 1 10 100
Favours PPV23 Favours PCV7
(1) 48 months
Analysis 2.3. Comparison 2 Comparison PPV-23 versus PCV-7, Outcome 3 Hospital admission, any cause:
at least 1 episode.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 2 Comparison PPV-23 versus PCV-7
Outcome: 3 Hospital admission, any cause: at least 1 episode
Study or subgroup PPV23 PCV7 Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dransfield 2009 (1) 24/90 26/91 0.91 [ 0.47, 1.74 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PPV23 Favours PCV7
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Analysis 2.4. Comparison 2 Comparison PPV-23 versus PCV-7, Outcome 4 Acute exacerbation COPD.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 2 Comparison PPV-23 versus PCV-7
Outcome: 4 Acute exacerbation COPD
Study or subgroup PPV23 PCV7 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dransfield 2009 (1) 43/90 42/91 1.07 [ 0.60, 1.91 ]
0.01 0.1 1 10 100
Favours PPV23 Favours PCV7
(1) 48 months
Analysis 2.5. Comparison 2 Comparison PPV-23 versus PCV-7, Outcome 5 Adverse effects.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 2 Comparison PPV-23 versus PCV-7
Outcome: 5 Adverse effects
Study or subgroup PPV23 PCV7 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fatigue
Dransfield 2009 39/63 23/57 2.40 [ 1.15, 5.00 ]
2 Headache
Dransfield 2009 13/63 8/57 1.59 [ 0.61, 4.18 ]
3 Fever
Dransfield 2009 3/63 4/57 0.66 [ 0.14, 3.10 ]
4 Pain
Dransfield 2009 39/63 31/57 1.36 [ 0.66, 2.82 ]
5 Redness or discolouration≤ 15 cm
Dransfield 2009 27/63 10/57 3.53 [ 1.51, 8.21 ]
6 Redness or discolouration > 15 cm
Dransfield 2009 2/63 0/57 4.67 [ 0.22, 99.46 ]
0.2 0.5 1 2 5
Favours PPV23 Favours PCV7
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(. . . Continued)
Study or subgroup PPV23 PCV7 Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
7 Localised swelling
Dransfield 2009 23/63 15/57 1.61 [ 0.74, 3.52 ]
8 Limitation of arm movement
Dransfield 2009 29/63 18/57 1.85 [ 0.88, 3.90 ]
0.2 0.5 1 2 5
Favours PPV23 Favours PCV7
Analysis 3.1. Comparison 3 Analysis by follow-up period/subgroup, Outcome 1 Pneumonia by lung function
at baseline.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 1 Pneumonia by lung function at baseline
Study or subgroup Vaccine Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 FEV1 < 40% expected
Alfageme 2006 12/132 20/114 53.6 % 0.48 [ 0.23, 1.00 ]
Subtotal (95% CI) 132 114 53.6 % 0.48 [ 0.23, 1.00 ]
Total events: 12 (Vaccine), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 FEV1 ≥ 40% expected
Alfageme 2006 13/166 13/184 46.4 % 1.12 [ 0.50, 2.48 ]
Subtotal (95% CI) 166 184 46.4 % 1.12 [ 0.50, 2.48 ]
Total events: 13 (Vaccine), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 298 298 100.0 % 0.71 [ 0.41, 1.22 ]
Total events: 25 (Vaccine), 33 (Control)
Heterogeneity: Chi2 = 2.36, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 2.36, df = 1 (P = 0.12), I2 =58%
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Analysis 3.2. Comparison 3 Analysis by follow-up period/subgroup, Outcome 2 Hospital admission, any
cause: by follow-up periods.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 2 Hospital admission, any cause: by follow-up periods
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 6-12 months
Kostinov 2014 (1) 1/100 3/100 19.7 % 0.33 [ 0.03, 3.19 ]
Steentoft 2006 (2) 18/37 6/12 30.9 % 0.95 [ 0.26, 3.48 ]
Subtotal (95% CI) 137 112 50.7 % 0.71 [ 0.23, 2.12 ]
Total events: 19 (Vaccine), 9 (Control)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 12-24 months
Yilmaz 2013 9/104 5/24 49.3 % 0.36 [ 0.11, 1.19 ]
Subtotal (95% CI) 104 24 49.3 % 0.36 [ 0.11, 1.19 ]
Total events: 9 (Vaccine), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.095)
Total (95% CI) 241 136 100.0 % 0.54 [ 0.23, 1.22 ]
Total events: 28 (Vaccine), 14 (Control)
Heterogeneity: Chi2 = 1.34, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 0.66, df = 1 (P = 0.42), I2 =0.0%
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Analysis 3.3. Comparison 3 Analysis by follow-up period/subgroup, Outcome 3 Hospital admission,
cardiorespiratory-related: by follow-up periods.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 3 Hospital admission, cardiorespiratory-related: by follow-up periods
Study or subgroup Vaccine Control log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 7-12 months
Leech 1987 76 84 -0.1112 (0.212) 100.0 % 0.89 [ 0.59, 1.36 ]
Subtotal (95% CI) 76 84 100.0 % 0.89 [ 0.59, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 13-18 months
Leech 1987 71 79 0.1967 (0.2916) 100.0 % 1.22 [ 0.69, 2.16 ]
Subtotal (95% CI) 71 79 100.0 % 1.22 [ 0.69, 2.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 19-24 months
Leech 1987 52 60 -0.361 (0.5352) 100.0 % 0.70 [ 0.24, 1.99 ]
Subtotal (95% CI) 52 60 100.0 % 0.70 [ 0.24, 1.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 1.13, df = 2 (P = 0.57), I2 =0.0%
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Analysis 3.4. Comparison 3 Analysis by follow-up period/subgroup, Outcome 4 Emergency department
visit, any cause: by follow-up period.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 4 Emergency department visit, any cause: by follow-up period
Study or subgroup Vaccine Control Odds Ratio Odds Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 3-12 months
Yilmaz 2013 6/114 5/28 0.26 [ 0.07, 0.91 ]
2 12-24 months
Yilmaz 2013 5/108 5/25 0.19 [ 0.05, 0.73 ]
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Analysis 3.5. Comparison 3 Analysis by follow-up period/subgroup, Outcome 5 Emergency visits (by cause).
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 5 Emergency visits (by cause)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Due to URTI
Leech 1987 0.258 (0.33) 100.0 % 1.29 [ 0.68, 2.47 ]
Subtotal (95% CI) 100.0 % 1.29 [ 0.68, 2.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 Due to LRTI
Leech 1987 -0.0033 (0.148) 100.0 % 1.00 [ 0.75, 1.33 ]
Subtotal (95% CI) 100.0 % 1.00 [ 0.75, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
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(. . . Continued)
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
3 Due to pneumonia
Leech 1987 -0.008 (0.325) 100.0 % 0.99 [ 0.52, 1.88 ]
Subtotal (95% CI) 100.0 % 0.99 [ 0.52, 1.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 3.6. Comparison 3 Analysis by follow-up period/subgroup, Outcome 6 At least 1 COPD
exacerbation: varying follow-up.
Review: Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease
Comparison: 3 Analysis by follow-up period/subgroup
Outcome: 6 At least 1 COPD exacerbation: varying follow-up
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 12 months
Kostinov 2014 (1) 54/100 65/100 52.5 % 0.63 [ 0.36, 1.12 ]
Steentoft 2006 (2) 30/37 9/12 4.5 % 1.43 [ 0.31, 6.69 ]
Subtotal (95% CI) 137 112 57.0 % 0.70 [ 0.41, 1.19 ]
Total events: 84 (Vaccine), 74 (Control)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 > 12-24 months
Furumoto 2008 (3) 14/24 23/31 14.7 % 0.49 [ 0.16, 1.53 ]
Yilmaz 2013 18/104 12/24 28.3 % 0.21 [ 0.08, 0.54 ]
Subtotal (95% CI) 128 55 43.0 % 0.30 [ 0.15, 0.63 ]
Total events: 32 (Vaccine), 35 (Control)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 265 167 100.0 % 0.53 [ 0.34, 0.81 ]
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 116 (Vaccine), 109 (Control)
Heterogeneity: Chi2 = 5.66, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Chi2 = 3.20, df = 1 (P = 0.07), I2 =69%
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A D D I T I O N A L T A B L E S
Table 1. Comparison of studies
Study ID
(n)
Vaccine 1 Compari-
son
Setting/
Follow-
up,
months
Mean age/
% male
Mean
FEV1 (L)
or % pre-
dicted
% AE 12
months
% ICS % prior
pneumo-
nia
% current
smokers
Alfageme
2006 (n =
600)
23-valent
PPV
No vaccine Seville,
Spain/32
median
69/98 1.2 ± 0.8 NA NA 18 24
Davis
1987 (n =
103)
14-
valent PPV
0.5 mL SC
Saline 0.5
mL SC
New York,
USA/24 to
32
63/NA 1.4 ± 0.7 NA NA 26 43
Dransfield
2009 (n =
181)
23-valent
PPV
7-valent
PCV
USA 21
centres/48
64/37 45% 15 65 45 36
Furumoto
2008 (n =
55 with
COPD )
14-
valent PPV
+ influenza
Influenza Kyushu &
Okinawa,
Japan/24
69/64 NA NA NA NA NA
Kostinov
2014 (Rus-
sian paper)
(n = 200)
23-valent
PPV
No vaccine Russia/12 30-70/36 NA NA NA NA NA
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Table 1. Comparison of studies (Continued)
Leech
1987 (n =
189)
14-
valent PPV
+ influenza
Saline + in-
fluenza
Montreal
Canada/24
68/71 0.95 ± 0.3 NA NA NA NA
Lin 2013
(abstract&
poster) (n
= 36)
23-valent
PPV
Saline Taipei,
Taiwan/12
71/89 1%to45% > 50 100 (>
1500 mcg/
d)
> 50 37
Steentoft
2006 (n =
49)
23-
valent PPV
0.5 mL SC
No vaccine Denmark/
6
65-72/55 0.8 to 1.2 NA OCS 24% NA 46
Teramoto
2007 (Ab-
stract) (n =
196)
23-valent
PPV
No vaccine Japan/24 78/NA NA NA NA NA NA
Trofimov
2010 (Rus-
sian paper)
(n = 45)
23-valent
PPV
No vaccine Russia/6 55/67 62% NA NA NA NA
Ya
Tseimakh
2006 (ab-
stract) (n =
373)
23-valent
PPV
No vaccine Russia/6 69/57 62% 100 OCS not
allowed
NA 60
Yilmaz
2013 (ab-
stract
& unpub-
lished pa-
per) (n =
144)
23-valent
PPV
Placebo Turkey &
UK/24
65/93 1.4 L ± 0.6 NA NA NA NA
AE = acute exacerbation of COPD.
ICS = inhaled corticosteroids.
OCS = oral corticosteroids.
PCV = diphtheria-conjugated pneumococcal polysaccharide vaccine.
PPV = pneumococcal polysaccharide vaccine.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
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COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to retrieve relevant trials from the CAGR
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 MeSH DESCRIPTOR Pneumococcal Vaccines
#8 ((vaccin* or immuni*) and pneum*)
#9 Pneumovax
#10 Pnu-Imune
#11 Pnu-Immune
#12 Prevnar
#13 “Pneumo 23”
#14 #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #6 and #14
[In search line #4, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, COPD]
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Appendix 3. Search strategies
CENTRAL search
#1 MeSH descriptor Lung Diseases, Obstructive, this term only
#2 MeSH descriptor Pulmonary Disease, Chronic Obstructive explode all trees
#3 emphysema*
#4 chronic* near/3 bronchiti*
#5 (obstruct*) near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#6 COPD
#7 COAD
#8 COBD
#9 AECB
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Pneumococcal Vaccines explode all trees
#12 pneum* near/3 (vaccin* or immuni*)
#13 Pneumovax or Pnu-Imune or Pnu-Immune or Prevnar or Prevenar or “Pneumo 23”
#14 (#11 OR #12 OR #13)
#15 (#10 AND #14)
MEDLINE search
1 exp Pulmonary Disease, Chronic Obstructive/
2 (obstruct$ adj3 (lung$ or respirat$ or pulmonar$) adj3 disease$).mp.
3 Bronchiti$.mp.
4 emphysema$.mp.
5 ((lung$ or thorax) adj3 hyperlucen$).mp.
6 (chronic adj5 obstruct$).mp.
7 (pulmonar$ or lung$ or airway$ or airflow$ or bronch$ or respirat$).mp.
8 6 and 7
9 (COPD or COAD).mp.
10 AECB.mp.
11 1 or 2 or 3 or 4 or 5 or 8 or 9 or 10
12 Pneumococcal Vaccines/
13 (pneum$ adj3 (vaccin$ or immuni$)).mp.
14 (Pneumovax or Pnu-Imune or Pnu-Immune or Prevnar or Prevenar or “Pneumo 23”)
15 12 or 13 or 14
16 11 and 15
17 (clinical trial or controlled clinical trial or randomized controlled trial).pt.
18 (randomized or randomised).ab,ti.
19 placebo.ab,ti.
20 dt.fs.
21 randomly.ab,ti.
22 trial.ab,ti.
23 groups.ab,ti.
24 or/16-22
25 Animals/
26 Humans/
27 24 not (24 and 25)
28 23 not 26
29 16 and 27
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Embase search
1 Chronic Obstructive Lung Disease/
2 Emphysema/
3 exp Lung Emphysema/
4 Chronic Bronchitis/
5 (obstruct$ adj3 (lung$ or respirat$ or pulmonar$) adj3 disease$).mp.
6 Bronchiti$.mp.
7 emphysema$.mp.
8 ((lung$ or thorax) adj3 hyperlucen$).mp.
9 (chronic adj5 obstruct$).mp.
10 (pulmonar$ or lung$ or airway$ or airflow$ or bronch$ or respirat$).mp.
11 9 and 10
12 (COPD or COAD).mp.
13 AECB.mp.
14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11 or 12 or 13
15 Pneumococcus Vaccine/
16 (pneum$ adj3 (vaccin$ or immuni$)).mp.
17 (Pneumovax or Pnu-Imune or Pnu-Immune or Prevnar or Prevenar or “Pneumo 23”)
18 15 or 16 or 17
19 14 and 18
20 Randomized Controlled Trial/
21 Controlled Study/
22 randomization/
23 Double Blind Procedure/
24 Single Blind Procedure/
25 Clinical Trial/
26 Crossover Procedure/
27 follow up/
28 exp prospective study/
29 or/19-27
30 (clinica$ adj3 trial$).mp.
31 ((singl$ or doubl$ or trebl$ or tripl$) adj5 (mask$ or blind$ or method$)).mp.
32 exp Placebo/
33 placebo$.mp.
34 random$.mp.
35 (latin adj3 square$).mp.
36 exp Comparative Study/
37 ((control$ or prospectiv$ or volunteer$) adj3 (trial$ or method$ or stud$)).mp.
38 (crossover$ or cross-over$).mp.
39 or/30-38
40 29 or 39
41 exp ANIMAL/
42 Nonhuman/
43 Human/
44 41 or 42
45 44 not 43
46 40 not 45
47 19 and 46
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WH A T ’ S N E W
Last assessed as up-to-date: 25 November 2016.
Date Event Description
23 November 2016 New search has been performed Searches updated for this review identified 5 additional
studies (Dransfield 2009; Kostinov 2014; Lin 2013;
Teramoto 2007; Yilmaz 2013) that compared vaccine
versus control and involved 606 participants. This re-
view was last updated in 2010. The review now in-
cludes a total of 12 studies involving 2171 participants
23 November 2016 New citation required and conclusions have changed This update, which includes additional studies, now
shows statistical significance in reducing the likelihood
of community-acquired pneumonia (odds ratio (OR)
0.62, 95% confidence interval (CI) 0.43 to 0.89), as
well as statistical significance in reducing the likeli-
hood of an acute exacerbation of chronic obstructive
pulmonary disease (COPD) (OR 0.60, 95% CI 0.39
to 0.9)
One included study (Dransfield 2009) compared 2
different vaccine types and found no significant differ-
ences for the primary outcomes
H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 4, 2006
Date Event Description
4 June 2014 Amended We included comparison of vaccine types.
13 May 2010 New citation required and conclusions have changed Wepromotedpneumonia to a primary outcome for the 2010
update and added ’Risk of bias’ tables. We included 3 new
studiesidentified by searches run up to March 2010
Data for community-acquired pneumonia changed the size
of the effect estimate, although it remained not statistically
significant. In the previous version of the review, the ORwas
0.89 (95% CI 0.58 to 1.37). With the addition of new data,
the pooled effect estimate was OR 0.72, 95% CI 0.51 to 1.
01
31 July 2008 Amended We converted this review to new review format.
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(Continued)
21 July 2006 New citation required and conclusions have changed We made substantive amendments.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Review authors promoted pneumonia from a secondary to a primary outcome in the 2010 update. For the 2016 version of the review,
review authors have changed the title to highlight the focus on the clinically relevant outcome of pneumonia. We have updated
the Background by including information on new vaccines and guidelines. Studies comparing different types of vaccines have been
conducted since the 2010 update, and we have included one of them (Dransfield 2009). Since the last update (in 2010), we have added
new standard Cochrane headings and tables assessing risk of bias and providing a summary of findings.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Pneumococcal Infections [mortality; ∗prevention & control]; Pneumococcal Vaccines [∗administration & dosage]; Pulmonary Disease,
Chronic Obstructive [∗complications; mortality]; Randomized Controlled Trials as Topic
MeSH check words
Humans; Middle Aged
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